Structure and mechanism of the RNA polymerase II CTD phosphatase Scp1 and large-scale preparation of the RNA polymerase II-TFIIF complex by Kamenski, Tomislav
Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und 
Pharmazie der Ludwig-Maximilians-Universität München 
 
 
 
	
	

	
 	
 !!"
 
 
Tomislav Kamenski 
aus Zagreb, Kroatien 
2006 
Erklärung 
Diese Dissertation wurde im Sinne von §13 Abs. 3 bzw. 4 der Promotionsordnung 
vom 29. Januar 1998 von Herrn Prof. Dr. Patrick Cramer betreut. 
 
Ehrenwörtliche Versicherung 
Diese Dissertation wurde selbständig, ohne unerlaubte Hilfe erarbeitet. 
 
München, den 2. Mai 2006 
 
 
 
 
 
 
 
Dissertation eingereicht am 4. Mai 2006 
1. Gutachter: Prof. Dr. Patrick Cramer 
2. Gutachter: Prof. Dr. Ralf-Peter Jansen 
Mündliche Prüfung am 29. Mai 2006 
Acknowledgements 
First of all I owe my gratitude to my PhD supervisor Prof. Patrick Cramer for providing 
me excellent conditions for independent research work and for constant support. 
I am most grateful to Claudia, for being a great companion on the long and difficult 
way of TFIIF project and for loud laughs at the time when the project did not seem 
promising. Toni Meinhart, thank you for being patient with me, while learning basics 
of crystallography. I would also like to thank Stefan Benkert for great effort in 
fermenting yeast, Marian Kalocay, for providing me with useful vectors and tips. 
Karim, thank you for accompanying me to fast food restaurants (willingly) after long 
days in the lab and Michela for good laughs and late evening jogging rounds. To 
Hubert, Florian, Laurent and other lab members, I am grateful for being great 
colleagues, always willing to help, and for nice atmosphere in the laboratory. I would 
like to thank especially Kathrin Gmelch for being an excellent diploma student, as 
well as Susanna Heilmeier for introducing me to phosphatase project. I am grateful to 
Anass for great collaboration, exchange of scientific views and I wish him all the luck 
in the continuation of the project. 
I would like to thank Katja Sträßer and Heidi Feldmann for providing great advice and 
being ready to teach me about yeast. 
I would also like to thank members of my PhD thesis committee, Alexander Brehm 
and Ralf-Peter Jansen for a lot of advice. 
I wish to thank Ita Grui, for her expertise on RNA biochemistry, as well as Prof. 
Ivana Weygand-uraševi for support even while being abroad. 
I thank Boehringer Ingelheim Fonds for generous financial support and possibility to 
meet other young motivated scientists with similar interests.  
Finally, I am deeply indebted to my family for all their help and support during my 
education. 
	


 
Summary 
1 Introduction 
1.1 Eukaryotic RNA polymerases ...................................................................... 1 
1.2 Structure of Pol II ......................................................................................... 2 
1.3 Eukaryotic transcription cycle....................................................................... 3 
1.4 TFIIF is a unique eukaryal general transcription factor ................................ 9 
1.4.1 Roles of TFIIF during PIC formation and promoter escape .................... 13 
1.4.2 Roles of TFIIF in elongation ................................................................... 14 
1.4.3 TFIIF interactions with Pol II ................................................................... 14 
1.5 Carboxy-terminal domain of Pol II (CTD) ................................................... 16 
1.6 CTD phosphorylation and transcriptional regulation .................................. 17 
1.7 CTD kinases .............................................................................................. 18 
1.8 CTD phosphatase Ssu72 ........................................................................... 19 
1.9 CTD phosphatases of the Fcp1 family ....................................................... 21 
1.10 Aims of this work........................................................................................ 24 
2 Materials and Methods 
2.1 Bacterial and yeast strains ......................................................................... 25 
2.2 Plasmids .................................................................................................... 26 
	


2.3 Media and supplements ............................................................................. 26 
2.4 Buffers and solutions.................................................................................. 27 
2.5 Bioinformatic tools...................................................................................... 29 
2.6 Molecular cloning techniques..................................................................... 29 
2.7 Preparation of competent cells................................................................... 31 
2.8 Electrophoretic methods ............................................................................ 31 
2.9 Preparation of samples for Edman sequencing ......................................... 32 
2.10 Protein expression in E. coli and selenomethionine labeling...................... 32 
2.11 Cloning and protein purification of CTD phosphatases .............................. 33 
2.12 Limited Proteolysis ..................................................................................... 34 
2.13 Crystallization and structure determination ................................................ 35 
2.14 Phosphatase kinetics and inhibitor studies ................................................ 36 
2.15 Activity assay with active site mutants ....................................................... 37 
2.16 Purification of Pol II core enzyme............................................................... 37 
2.17 Purification of Rpb4/7 subcomplex............................................................. 39 
2.18 Reconstitution of a Pol II-Fcp1 complex..................................................... 40 
2.19 Purification of TFIIF variants expressed in E. coli ...................................... 41 
2.20 Generation of a yeast strain overexpressing TFIIF .................................... 44 
2.21 Isolation of genomic DNA from yeast ......................................................... 45 
	


2.22 Yeast transformation.................................................................................. 45 
2.23 Small-scale Pol II-TFIIF tandem affinity purification (TAP)......................... 46 
2.24 Dot blot assay ............................................................................................ 47 
2.25 Large-scale isolation of Pol II-TFIIF complex from yeast ........................... 48 
2.25.1 Yeast fermentation.............................................................................. 48 
2.25.2 Harvesting and storage of yeast ......................................................... 49 
2.25.3 Large-scale purification of the Pol II-TFIIF complex............................ 49 
2.26 Purification of TFIIB.................................................................................... 50 
2.27 Purification of TBP core ............................................................................. 51 
2.28 Electrophoretic mobility shift assay ............................................................ 52 
2.29 Assembly of an initially transcribing complex ............................................. 52 
2.30 Isolation of RNA from protein preparations ................................................ 53 
2.31 Isolation of RNA from polyacrylamide gel .................................................. 53 
2.32 Identification of RNA .................................................................................. 54 
3 Results and Discussion 
3.1 Structure and mechanism of Pol II CTD phosphatases.............................. 56 
3.1.1 Domain organization and structure determination .................................. 56 
3.1.2 Overall structure ..................................................................................... 60 
3.1.3 Phosphatase activity............................................................................... 62 
	


3.1.4 Specific inhibition.................................................................................... 62 
3.1.5 Active center........................................................................................... 63 
3.1.6 Catalytic mechanism .............................................................................. 65 
3.1.7 CTD specificity........................................................................................ 67 
3.1.8 The Pol II subcomplex Rpb4/7 recruits Fcp1.......................................... 68 
3.2 Preparation of the Pol II-TFIIF complex ..................................................... 72 
3.2.1 Expression of TFIIF in E. coli.................................................................. 72 
3.2.2 Isolation of TFIIF from yeast ................................................................... 74 
3.2.3 Overexpression of TFIIF in yeast............................................................ 75 
3.2.4 Assembly of an initially transcribing complex (ITC) ................................ 79 
3.2.5 Presence of 5.8S rRNA in Pol II-TFIIF preparations............................... 81 
Conclusions.............................................................................................................. 83 
References............................................................................................................... 85 
 
 
 
 
Summary 
TFIIF is the only general transcription factor that has been implicated in the 
preinitiation complex assembly, open complex formation, initiation and transcription 
elongation. In addition, TFIIF stimulates Fcp1, a central phosphatase needed for 
recycling of RNA polymerase II (Pol II) after transcription by dephosphorylation of the 
Pol II C-terminal domain (CTD). This thesis reports the X-ray structure of the small 
CTD phosphatase Scp1, which is homologous to the Fcp1 catalytic domain. The 
structure shows a core fold and an active center similar to phosphotransferases and 
–hydrolases that solely share a DXDX(V/T) signature motif with Fcp1/Scp1. It was 
further demonstrated that the first aspartate in the signature motif undergoes metal-
assisted phosphorylation during catalysis, resulting in a phosphoaspartate 
intermediate that was structurally mimicked with the inhibitor beryllofluoride. 
Specificity may result from CTD binding to a conserved hydrophobic pocket between 
the active site and an insertion domain that is unique to Fcp1/Scp1. Fcp1 specificity 
may additionally arise from phosphatase recruitment near the CTD via the Pol II 
subcomplex Rpb4/7, which is shown to be required for Fcp1 binding to the 
polymerase in vitro. Until now, the main impediment in the high resolution 
crystallographic studies of TFIIF in complex with Pol II and other members of 
transcription machinery was unavailability of soluble, stoichiometric TFIIF complex in 
sufficient amounts. This thesis reports on the development of the overexpression 
system in yeast and a purification protocol that enabled for the first time to isolate 
milligram amounts of a pure and soluble, 15-subunit (~0,7 MDa) stoichiometric Pol II-
TFIIF complex. Such complex together with the promoter DNA, RNA, TBP and TFIIB 
assembles in vitro into the yeast initially transcribing complex, which can now be 
studied structurally. 
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1.1 Eukaryotic RNA polymerases 
In bacteria and archaea, a single kind of RNA polymerase synthesizes all of the cell’s 
RNA except the RNA primers employed in DNA replication. Eukaryotes, however, 
generally possess three different nuclear RNA polymerases, each responsible for 
synthesis of a different class of RNAs.  
RNA polymerase I (Pol I) is located in the nucleoli and synthesizes precursors of 
most ribosomal RNAs (rRNAs). RNA polymerase II (Pol II) occurs in the nucleoplasm 
and synthesizes mRNA precursors from protein-coding genes. RNA polymerase III 
(Pol III) also occurs in the nucleoplasm and synthesizes the precursors of 5S 
ribosomal RNA, the tRNAs, and a variety of other small nuclear and cytosolic RNAs. 
Recently discovered in plants, RNA polymerase IV (Pol IV) helps produce siRNAs 
that target de novo cytosine methylation events that play role in heterochromatin 
formation (Onodera et al., 2005). 
The central enzyme of eukaryotic transcription of all protein-coding genes is Pol II. It 
interacts with general transcription factors within the preinitiation complex (PIC), 
breaks these interactions upon initiation and promoter clearance and associates with 
a new set of factors during elongation, termination, and mRNA processing. Pol II is a 
multisubunit complex which consists of 12 subunits, which can be divided into three 
categories (Hahn, 2004). These are subunits of the core domain having homologous 
counterparts in bacterial Pol (Rpb1, 2, 3 and 11), subunits shared between all three 
nuclear polymerases (Rpb5, 6, 8, 10 and 12) and subunits specific to Pol II but not 
essential for transcription elongation (Rpb4, 7 and 9). The subunits that make the 
core of every RNA polymerase investigated thus far are homologous to subunits from 
all cellular RNA polymerases implying same basic structure and mechanism (Ebright, 
2000). 
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1.2 Structure of Pol II 
A wealth of information on the transcription mechanism was provided over the past 
years by high quality X-ray structures of bacterial polymerase (Zhang et al., 1999) 
and its complexes with GreB (Opalka et al., 2003) and -subunit (Mekler et al., 2002; 
Murakami et al., 2002; Vassylyev et al., 2002). The hallmark of eukaryotic 
transcription, however, was the structure of the 10-subunit core Pol II (Cramer et al., 
2001). This structure served as a starting point for further structures of the two 
transcribing complexes (Gnatt et al., 2001; Westover et al., 2004), the 12-subunit Pol 
II structure (Armache et al., 2003; Bushnell and Kornberg, 2003, Armache et al., 
2005), as well as its complexes with transcription factors TFIIB (Bushnell et al., 2004) 
and TFIIS (Kettenberger et al., 2003). Cryo electron microscopy complemented this 
data with the overall architecture of Pol II in complex with its coactivator Mediator 
(Davis et al., 2002) and with general transcription factor TFIIF (Chung et al., 2003).   
Pol II consists of a folded region that is responsible for mRNA synthesis, and the 
mobile C-terminal domain (CTD) not seen in the electron density (Cramer et al., 
2001; Figure 1). The core of the Pol II enzyme comprises Rpb3, 10, 11, 12 as well as 
the regions of Rpb1 and 2 which form the active center (Cramer et al., 2001). These 
subunits account for half of the mass of Pol II and are either shared or homologous 
between all cellular RNA polymerases. The center of the enzyme represents a deep 
cleft where incoming DNA enters from one side and the active site is buried at the 
base. The cleft is formed by four mobile elements of the enzyme, namely the core, 
the clamp, the shelf and the jaw-lobe that move relative to each other. It was 
observed in both open and closed conformation due to the clamp movement. The 
clamp is connected to the core through the set of flexible switches and can move by 
a swinging motion of up to 30 Å. In the structure of the 12-subunit Pol II (Figure 1), 
the clamp is locked by Rpb7 into a closed conformation (Armache et al., 2003; 
Bushnell et al., 2003). This however implies that during initiation double-stranded 
DNA template does not enter the active site cleft but rather the single-stranded DNA 
template strand is inserted deep into the cleft to reach the active site during open 
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complex formation. Rbp4 and 7 subunits additionally provide a binding surface for 
other factors and possibly for RNA exiting the elongating Pol II. 
 
Figure 1: Complete RNA polymerase II structure. Two standard views “front” and “top” are shown. 
The 12 subunits Rpb1-Rpb12 are colored according to the key below the views. Dashed lines 
represent disordered loops. Eight zinc ions and the active site magnesium ion are depicted as cyan 
spheres and a pink sphere, respectively. Adopted from (Armache et al., 2005). 
 
1.3 Eukaryotic transcription cycle 
The control of gene expression is achieved by a common mechanism that underlines 
selective binding of proteins to specific control sequences elements in order to 
modulate the rate of transcription initiation. Pol II, unlike bacterial RNA polymerases 
(Pol), possesses little if any inherent ability to bind to its promoters. In bacteria a 
single polypeptide, the σ subunit recognizes promoter sequences, promotes 
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conformational changes in the Pol-DNA complex upon initiation and directly interacts 
with some transcription activators. In contrast, eukaryotic Pol II and five general 
transcription factors (GTFs), called TFIIB, -D, -E, -F, and -H, which substitute for σ 
functions, position onto the core promoter in a state termed the preinitiation complex 
(PIC, Figure 2). Additionally TFIIA can contribute stabilizing interactions (Pugh, 2000; 
Bleichenbacher et al., 2003). Archaea rely only on two essential general factors, 
TATA-binding protein (TBP) and TFB (related to the TFIIB in Pol II). 
Figure 2: Pol II pathway of transcription initiation and reinitiation. Adopted from (Hahn, 2004). 
 
TBP together with 14 TBP-associated factors (TAFs) forms the multisubunit TFIID 
complex. However, at some promoters TBP is sufficient for promoter recognition 
(Kuras et al., 2000; Li et al., 2000). TBP has a core domain consisting of two 
imperfect repeats which form a saddle-shaped molecule that binds the widened 
minor groove of an 8-bp TATA element of TATA-containing promoters. Binding of 
TBP causes unwinding of about a third of a helical turn and bending the DNA about 
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80 Å towards the major groove (Kim et al., 1993a; Kim et al., 1993b). The role and 
mode of possible binding in TATA-less promoters is not clear. In addition to TBP, 
higher eukaryotes have one or two copies of genes encoding TBP-related factors 
(TRFs) (Hochheimer and Tjian, 2003). Their role is to promote transcription from a 
subset of protein-coding genes in a cell type-specific fashion. The TBP-DNA complex 
creates a large asymmetric interface, a platform for binding other components of the 
transcription machinery.  
Nearly all of TAFs have been conserved through evolution (Albright and Tjian, 2000; 
Green, 2000; Tora, 2002). TAFs function in promoter recognition and in positive and 
negative regulation of transcription. In higher eukaryotes TFIID have alternative 
subunits that change the composition of TFIID in a cell type- and development-
specific fashion. Some TAFs are also subunits of complexes lacking TBP involved in 
covalent chromatin modification and transcriptional coactivation (Green, 2000). 
Current structural information on TFIID includes X-ray structures of several individual 
subunits which reveal histone fold domains (Xie et al., 1996; Werten et al., 2002, 
Gangloff et al., 2001). The general architecture of the whole TFIID complex was 
revealed by electron microscopy and showed three lobes of a horseshoe in both 
closed and open configurations (Andel et al., 1999; Brand et al., 1999). According to 
immune localization experiments, TBP is positioned in the center lobe on the inside 
of the horseshoe. Overall TFIID protects 40-60 bp of DNA from DNase I cleavage 
(Sanders et al., 2002; Chi et al., 1995). However TFIID is not universally required at 
all promoters (Freiman et al., 2001; Shen et al., 2003) but rather some TAFs are 
important for gene regulation.  
TFIIA and TFIIB specifically and independently interact with TBP and DNA (Nikolov 
et al., 1995; Geiger et al., 1996; Tan et al., 1996). TFIIA stabilizes TBP-DNA binding 
(Weideman et al., 1997) and strongly promotes binding of TFIID to DNA through 
competition with the TAF1 N-terminal domain that occludes the DNA-binding surface 
of TBP when TFIID is not bound to DNA (Kokubo et al., 1998; Liu et al., 1998; 
Sanders et al., 2002). Moreover, it was demonstrated that TFIIA can stimulate basal 
transcription by interaction with both TFIIF and TFIIE (Langelier et al., 2001).   
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The general transcription factor TFIIB consists of two domains conserved in Pol III 
and archaea factors Brf1 and TFB. A flexible linker connects N-terminal Zn-ribbon 
domain to the C-terminal core domain (TFIIBc) that binds the TBP-DNA subcomplex 
(Chen and Hahn, 2003; Pardee et al., 1998). The functional surface of the ribbon 
domain is conserved in TFIIB, Brf1 and TFB and is essential for recruitment of Pol II 
to the PIC (Hahn and Roberts, 2000). The linker connecting the ribbon and core 
domains contains a short conserved block of sequence that forms a loop termed the 
B-finger, which is positioned in the active site of Pol II (Bushnell et al., 2004). 
TFIIE acts at a late stage in the PIC formation, interacting with TFIIB, TFIIH, Pol II, as 
well as with the promoter DNA (Maxon et al., 1994; Orphanides et al., 1996, Roeder, 
1996). Together with TFIIH, TFIIE participates in promoter melting and open complex 
formation. In higher eukaryotes TFIIE consists of two highly charged subunits, 
referred to as α and β, respectively. The acidic C-terminus of TFIIEα and conserved 
zinc-finger domain were mapped to interact with TFIIH (Okamoto et al., 1998). The 
central core region of the β-subunit is essential for basal and activated transcription 
and binds to double-stranded DNA. The C-terminal half of TFIIEβ contains two basic 
stretches that interact with TFIIB, RAP30 subunit of TFIIF and single-stranded DNA 
(Okamoto et al., 1998). NMR studies have shown that the TFIIEβ region with 
homology to TFIIF forms a winged helix domain (Okuda et al., 2000). Structural 
information on TFIIEα includes the structure of the archaeal homolog, TFE that 
adopts a winged helix-turn-helix fold (Meinhart et al., 2003a) and the zinc-finger 
domain, composed of one α-helix and five β-strands (Okuda et al., 2004). Three-
dimensional envelopes of the α/β particles were analyzed by electron microscopy 
and showed an elongated structure composed of three distinct modules (Jawhari et 
al., 2006). 
TFIIH is a 10-subunit complex, by size and complexity comparable to Pol II itself. It 
contains helicase activities that unwind DNA and form a transcription bubble 
(Svejstrup et al., 1996; Coin and Egly, 1998). The overall architecture of human 
TFIIH reveals a ring-like structure that could easily accommodate double-stranded 
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DNA (Schultz et al., 2000). TFIIH also comprises a kinase that phosphorylates the 
Pol II CTD during the transition from initiation to elongation (see chapter 1.7). Both 
enzymatic activities of TFIIH are stimulated by TFIIE (Ohkuma and Roeder, 1994).  
The core promoter is a minimal DNA sequence needed to specify nonregulated or 
basal transcription and serves as a platform for recruitment of the transcription 
machinery (Cosma, 2002). Promoters of protein-coding genes contain one or more of 
the following DNA elements: TATA (TBP-binding site), BRE (TFIIB-recognition 
element), Inr (Initiator element) and DPE (downstream promoter element) (Smale 
and Kadonaga, 2003; Figure 3). Their role is to unidirectionally guide the 
transcription machinery to the promoter. However, only 30% of mRNA genes 
analyzed in Drosophila melanogaster have promoters with a recognizable TATA 
element (Ohler et al., 2002). In archaea the primary determinant of transcription 
orientation is the BRE (Bell et al., 1999; Littlefield et al., 1999). Inr and DPE serve as 
binding sites for certain TAFs, subunits of TFIID (Burke and Kadonaga, 1997). 
Figure 3: Summary of human general transcription factor protein-DNA crosslinks at a 
promoter. Top line represents promoter DNA with the position of functional elements indicated. Arrow 
represents the transcription start site. Adopted from (Hahn, 2004). 
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During initiation, 11-15 base pairs of DNA surrounding the transcription start site are 
melted and the template strand of the promoter is positioned within the active site 
cleft of Pol II to form the open complex (Wang et al., 1992). Upon synthesis of first 
phosphodiester bond of RNA, many of the 3-10 nucleotides long abortive products 
are formed before Pol II initiates productive synthesis of full-length RNAs (Luse and 
Jacob, 1987; Holstege et al., 1997). After the RNA reaches a length of 30 
nucleotides, Pol II is thought to release its contacts with the core promoter and enter 
the stage of transcription elongation. Many of the general transcription factors remain 
at the promoter after initiation in the form of the so-called scaffold complex 
(Yudkovsky et al., 2000), which can rapidly recruit the remaining general factors to 
promote transcription reinitiation.  
In the transcription elongation complex (TEC), incoming DNA is unwound before the 
polymerase active site and is rewound beyond it to form the exiting duplex. In the 
unwound region, known as the transcription bubble, the DNA template strand forms a 
hybrid duplex with the nascent pre-mRNA. Pol II maintains the bubble, selects 
nucleoside triphosphates in a template-directed manner, synthesizes RNA, 
translocates along the DNA and separates RNA from DNA at the upstream end of 
the hybrid. The elongating Pol II recruits many factors that promote productive RNA 
chain elongation (Table 1), by enhancing the elongation rate, or by regulating RNA 
processing, RNA export and chromatin modification (Bentley, 2002).  
Far less is known on the mechanism of transcription termination in eukaryotes. 
Recently, however, a 5’-3’ riboexonuclease (yeast Rat1 and human Xrn2) has been 
implicated in the process (Kim et al., 2004; Teixeira et al., 2004; West et al., 2004). 
The exonuclease travels with Pol II and gains access to the nascent RNA after 
endonucleolytic cleavage site at the poly(A) site or at a second cotranscriptional 
cleavage site (CoTC). However, this degradation can occur even without eliciting 
termination, implying that it is not sufficient to cause Pol II release (Luo et al., 2006). 
Rather, Rat1 is critical for recruitment of 3’-processing factors and for correct 3’-end 
formation, but is not a dedicated transcription factor (Luo et al., 2006). 
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Table 1: Human transcription elongation factors that modulate rate of elongation (Sims et al., 
2004) 
Elongation factor Function 
TFIIF Alleviates pausing, stimulates the rate of Pol II, modulates TFIIS 
TFIIS Stimulates Pol II-mediated cleavage of nascent transcript to alleviate arrest 
Elongins Alleviates pausing, stimulates the rate of Pol II, Ub-related events? 
ELL Alleviates pausing, stimulates the rate of Pol II 
DSIF Stimulates elongation, suppresses early transcript termination, stimulates capping 
NELF Halts Pol II to allow timely 5’-capping, checkpoint control 
CSB Stimulates elongation, modulates TFIIS, has a role in rescuing Pol II at DNA lesions and 
transcription-coupled nucleotide excision repair 
Fcp1 Stimulates elongation, recycles Pol II, role in capping  
Spt6 Stimulates elongation, modulates chromatin structure, histone chaperone activity 
HDAg Stimulates elongation, binds Pol II, displaces NELF, functionally distinct from TFIIF 
 
1.4 TFIIF is a unique eukaryal general transcription factor  
TFIIF is the only general transcription factor that has been implicated in the formation 
of the PIC, open complex formation, initiation as well as elongation. It was initially 
purified as a factor that directly binds immobilized Pol II (Sopta et al., 1985). In yeast 
cells about 50% of Pol II is found associated with the general transcription factor 
TFIIF (Rani et al., 2004). 
In humans TFIIF forms a heterodimer of RAP30 and RAP74 subunits, named after 
their apparent electrophoretic mobility in SDS gels. The human RAP74 polypeptide 
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(517 amino acids; calculated mass 58 kDa) comprises a globular N-terminal domain 
that binds RAP30 (Wang and Burton, 1995), a highly charged central linker region, 
and a globular C-terminal domain involved in the interaction with Pol II (Fang and 
Burton, 1996), TFIIB (Wang and Burton, 1995) and Fcp1 (Chambers et al., 1995; 
Kobor et al., 2000). The human RAP30 polypeptide (249 amino acids, 28 kDa) is 
composed of an N-terminal domain that binds RAP74 and TFIIB (Fang and Burton, 
1996), a central domain that interacts with Pol II (McCracken et al., 1991; Sopta et 
al., 1989), and a cryptic C-terminal DNA-binding domain with similarity to that found 
in members of the 70 family of bacterial sigma factors (Garret et al., 1992; Tan et al., 
1994). 
The yeast TFIIF homolog consists of three polypeptides named Tfg1, Tfg2, and Tfg3 
(Henry et al., 1994). The Tfg1 polypeptide is homologous to the human RAP74 but 
significantly larger (735 versus 517 amino acids). Similarly, the Tfg2 polypeptide is 
homologous to, but significantly larger than, the human RAP30 (400 versus 249 
amino acids). Tfg3 has no counterpart in mammalian TFIIF. Additionally known as 
Anc1, Swp29, TAF30, or TAF14, it belongs to a newly described family of proteins 
containing a conserved YEATS domain, the function of which is unknown (Cairns et 
al., 1996; Henry et al., 1994; John et al., 2000). In yeast, members of this family 
include components of complexes involved in chromatin silencing, histone 
acetyltransferase complex and chromatin remodeling complex (Masson et al., 2003; 
Poon et al., 1995; Zhang, 2004). Accordingly, Tfg3 is part of chromatin remodeling 
complexes RSC and INO80, and of the histone H3-acetyltransferase complex NuA3. 
Interactions with the Tfg1 subunit of TFIIF, and the TAF2 subunit of the general 
transcription factor TFIID were reported, suggesting a common regulatory function 
(Kabani et al., 2005). Strains devoid of Tfg3 are viable but thermosensitive, 
suggesting that Tfg3 plays important yet dispensable roles in the cell.  
For RAP74, structural information is available for the human N-terminal interaction 
domain, as well as a short C-terminal RAP74 domain in free and Fcp1 interacting 
helix bound state (Table 2, Figure 4). Additionally, the structure of the C-terminal 
DNA-binding domain of RAP30 was solved by NMR (Figure 4B). The X-ray structure 
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of the RAP30/RAP74 interaction domain heterodimer at 1.7 Å resolution reveals a 
single core structure consisting of three interwoven β-barrels, a novel “triple barrel” 
dimerization fold (Gaiser et al., 2000) (Figure 4A). Together with mutational data, the 
structure suggests that interactions with the transcription apparatus are mediated not 
only by this triple β-barrel, but also via flexible loops and - and β-structures 
extending from it (Gaiser et al., 2000). The RAP30 C-terminal domain that contains a 
cryptic DNA-binding motif, was demonstrated by NMR to be similar to the “winged” 
helix-turn-helix DNA-binding domains of linker histone H5 and hepatocyte nuclear 
transcription factor HNF3/forkhead (Groft et al., 1998) (Figure 4B). 
Table 2: Available structural information on TFIIF 
 
Like the C-terminal domain of RAP30, which may be responsible for nonspecific DNA 
binding, the C-terminal domain of RAP74 possesses a canonical winged-helix fold 
common to HNF-3γ, the linker histones H1 and H5, and a large family of so-called 
forkhead transcription factors (Figure 4C; Kamada et al., 2001; Nguyen et al., 
2003a). However, the surface electrostatic properties of this compact domain differ 
significantly from other winged-helix DNA-binding domains. RAP74 has been shown 
to interact with the TFIIF-associated C-terminal domain phosphatase, Fcp1, and a 
putative phosphatase binding site has been identified within the RAP74 winged-helix 
domain. A cocrystal structure of the winged-helix domain of human RAP74 bound to 
Structure Source Experimental technique 
(PDB code) 
Reference 
RAP30 DNA-binding domain  H. sapiens NMR (1bby, 2bby) Groft et al., 1998 
RAP30/RAP74 interaction domain  H. sapiens X-ray (1f3u) Gaiser et al., 2000 
RAP74 subunit C-terminal domain  H. sapiens X-ray (1i27); 
NMR (1nha) 
Kamada et al., 2001; 
Nguyen et al., 2003a 
RAP74 C-terminal domain complexed 
with Fcp1 C-terminal peptide 
H. sapiens X-ray (1j2x); 
NMR (1onv) 
Kamada et al., 2003; 
Nguyen et al., 2003b 
Pol II-TFIIF architecture S. cerevisiae Cryo-EM Chung et al., 2003 
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the alpha-helical C-terminus of human Fcp1 (residues 944-961) was reported (Figure 
4D; Kamada et al., 2001; Nguyen et al., 2003b). Similarly to the free RAP74 C-
terminal domain, when in the complex, it also forms a winged-helix domain consisting 
of three consecutive α-helices followed by an antiparallel β-sheet. Interestingly, the 
free C-terminal Fcp1 domain is devoid of any stable structural element but adopts a 
17-residue α-helix upon interaction with RAP74 (Figure 4D). 
Figure 4: Available structures of human TFIIF. (A) X-ray structure of the RAP30/RAP74 interaction 
domain at 1.7 Å (PDB code 1i27, Gaiser et al., 2000); (B) NMR structure of the RAP30 DNA binding 
domain (PDB code 1bby, Groft et al., 1998). (C) X-ray structure of the RAP74 subunit C-terminal 
domain (PDB code 1i27, Kamada et al., 2001); (D) X-ray structure of the RAP74 subunit C-terminal 
domain complexed with Fcp1 C-terminal peptide (PDB code 1j2x, Kamada et al., 2003). Figures were 
prepared with PyMol (www.pymol.org). 
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1.4.1 Roles of TFIIF during PIC formation and promoter escape 
TFIIF recruits Pol II to promoter DNA during PIC formation (Conaway et al.; 1991; 
Flores et al., 1991; Orphanides et al., 1996). Chromatin immunoprecipitation (ChIP) 
experiments localized TFIIF predominantly at the promoter (Krogan et al., 2002; 
Pokholok et al., 2002) region. Photo-cross-linking experiments showed that TFIIF 
binds both upstream of the TATA element and downstream of the transcription start 
site (Forget et al., 2004) suggesting that promoter DNA wraps around the mobile 
clamp of Pol II. It seems that the location of RAP74 is centered downstream of the 
first nucleotide to be transcribed whereas that of RAP30 is centered on the TATA box 
and immediately downstream of it (see chapter 1.3, Figure 3).  
A role for TFIIF in start site selection was uncovered in a genetic screen for 
suppressors of the cold-sensitive growth defect associated with the sua7-1-encoded 
TFIIB (Sun and Hampsey, 1995). Analyses of double mutant strains demonstrated 
functional interactions between the Tfg1 mutations and mutations in Tfg2, TFIIB, and 
Pol II that also confer alterations in start site utilizations (Ghazy et al., 2004). Thus 
TFIIB and TFIIF are critical determinants of start site selection in S. cerevisiae. 
However, the mechanisms by which altered forms of these factors affect start site 
selection remain unknown.  
TFIIF is further required for the entry of TFIIE and TFIIH into the PIC (Conaway et al., 
1991; Flores et al., 1992; Conaway et al., 1990a), Together with TFIIE, TFIIF 
participates in DNA strand separation by inducing the wrapping of DNA around Pol II 
(Coulombe and Burton, 1999). It displays dual roles in promoter escape, by 
cooperating with TFIIH to modulate premature arrest of early elongation 
intermediates, and, in a reaction dependent on TFIIF elongation activity, by 
increasing the processivity of very early elongation intermediates (Yan et al., 1999a). 
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1.4.2 Roles of TFIIF in elongation 
Following its release from the transcription initiation complex, TFIIF reassociates with 
the TEC in particular when Pol II complex has stalled (Zawel et al., 1995). ChIP 
experiments localized TFIIF also in the coding and in 3’-untranslated region (Krogan 
et al., 2002; Pokholok et al., 2002). TFIIF appears to represent an active elongation 
factor, but does not remain associated with the actively moving Pol II. TFIIF 
associates with multiple elongation factors including Spt5 of DSIF (Lindstrom et al., 
2003), and components of the PAF complex (Shi et al., 1997). Moreover TFIIF 
appears to influence the TFIIS cleavage factor (Elmendorf et al., 2001; Zhang et al., 
2003). In the absence of TFIIF, TFIIS supports entry of Pol II into the backtracking, 
RNA cleavage and restart pathway (Zhang et al., 2003). TFIIF diminishes the time 
Pol II is paused and stimulates the rate of Pol II transcription elongation (Flores et al., 
1989; Price et al., 1989; Bengal et al., 1991; Izban and Luse, 1992; Tan et al., 1994). 
Consequently, TFIIF is an established elongation factor which has important role on 
the regulation of Pol II TEC. 
The initiation and elongation activities of TFIIF are regulated mostly by the 
phosphorylation of RAP74 (Kitajima et al., 1994) largely by the TAF250 subunit of 
TFIID, and TFIIH (Ohkuma and Roeder, 1994; Dikstein et al., 1996; Yankulov and 
Bentley, 1997; Yonaha et al., 1997). In addition an autophosphorylation activity was 
reported (Rossignol et al., 1999). Mutational analysis strongly suggested that 
autophosphorylation regulates the transcription elongation process. In accordance 
with its roles in initiation and elongation, TFIIF has the ability to associate with both 
hypo- and hyperphosphorylated form of Pol II (Sims et al., 2004).  
 
1.4.3 TFIIF interactions with Pol II 
The general architecture of the Pol II-TFIIF complex at low resolution (18 Å) 
determined by cryo-electron microscopy and single particle analysis showed density 
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due to TFIIF not concentrated in one area, but rather widely distributed across the 
surface of polymerase (Chung et al., 2003; Figure 5).  
Figure 5: EM architecture of the Pol II-TFIIF complex (Chung et al., 2003). Pol II is an orange 
surface with TFIIF density in blue. The complex is shown in ”top” orientation (as that in Figure 1, right). 
Also shown is a model for downstream double-stranded DNA entering the active site cleft (blue and 
green helix). Figure was adopted from (Hahn, 2004). 
 
The distribution of Tfg2 was very similar to that reported for the  subunit in the 
bacterial RNA polymerase holoenzyme, consisting of a series of discrete globular 
domains extending along the polymerase active site cleft connected by extended 
linkers (Murakami et al., 2002; Vassylyev et al., 2002). The authors (Chung et al., 
2003) postulate Tfg2 as a true structural homolog of the bacterial  factor. The 
bacterial  factor serves 2 distinct roles: recognizing the -10 and -35 regions of the 
promoter and facilitating the formation of an unwound region of DNA surrounding the 
transcription start site (Gross et al., 1998). The role in promoter binding recognition 
entails not only promoter binding but also the capacity of  to disrupt a nonspecific 
RNA polymerase – DNA complex. In eukaryotes this role is carried out by TFIIF 
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(Conaway and Conaway, 1990; Killeen and Greenblatt, 1992; Tan et al., 1995). 
Additional TFIIF density was located along the length of the active site cleft of 
polymerase, starting behind the wall, near subunit Rpb12, next to the protrusion, 
along the top of the clamp, past the downstream end of the active site cleft near 
Rpb5, and into the Rpb1/Rpb8 feet (Figure 5). This is consistent with the previously 
reported interaction of the middle region of RAP30 and Rpb5 by GST pull-down 
assay (Wei et al., 2001). A significant amount of TFIIF density probably not related to 
Tfg2 is closely associated with the Rpb4/7 subcomplex of Pol II, which has a well-
established tendency to dissociate from the rest of the enzyme. 
 
1.5 Carboxy-terminal domain of Pol II (CTD) 
The CTD is a unique tail-like feature of the largest Pol II subunit that consists of 26 
(yeast) and 52 (human) heptapeptide repeats of the consensus sequence Tyr1-Ser2-
Pro3-Thr4-Ser5-Pro6-Ser7. However yeast requires at least eight repeats for viability 
(Nonet et al., 1987; West and Corden, 1995). The CTD integrates a whole range of 
nuclear events by binding proteins involved in mRNA biogenesis. Through its 
interaction with the Mediator complex, it plays a critical role in transcription activation 
(Thompson et al., 1993; Kim et al., 1994; Gerber et al., 1995). Furthermore, the CTD 
is required for efficient capping, splicing, cleavage and polyadenylation of mRNAs in 
vivo, and binds to processing factors in vitro (McCracken et al., 1997a; Hirose and 
Manley, 2000; Proudfoot et al., 2002). CTD-binding proteins recognize a specific 
CTD phosphorylation pattern, which changes during the transcription cycle due to the 
action of CTD-modifying enzymes. 
The CTD protrudes from an 80-residue linker bridging it to the core polymerase. The 
crystal structures of yeast Pol II do not reveal the CTD due to the mobility (Cramer et 
al., 2001; Armache et al., 2005). The free CTD is currently considered to be a flexible 
polypeptide chain with some residual structure and propensity to form β-turns. This 
view is mostly based on available NMR studies of a single consensus repeat 
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(Harding, 1992). Further studies by NMR and circular dichroism on the CTD 
polypeptide comprising of eight consensus repeats confirmed small population of β-
turn structures in water, increasing to 75% in trifluoroethanol (Cagas and Corden, 
1995; Bienkiewicz et al., 2000). Recent studies of a two-repeat CTD peptide with a 
central phosphorylated S2 residue, however, revealed a dynamic disordered 
ensemble (Noble et al., 2005). Disordered nature of the free CTD would not be 
surprising considering a great variety of interacting proteins. Assuming an extended 
β-strand conformation, the yeast CTD and linker would be ~650 Å and ~250 Å long, 
respectively, potentially reaching anywhere on the surface of Pol II (~150 Å in 
diameter; Meinhart et al., 2005). However, electron micrographs revealed some weak 
density attributed to the CTD which measured only 100 Å pointing out that CTD is 
mostly compact, at least in its unphosphorylated form (Meredith et al., 1996). 
Phosphorylation of the CTD results in a far more extended and more protease-
sensitive structure (Laybourn and Dahmus, 1989; Zhang and Corden, 1991). Over 
the last two decades, several different models for CTD structure have been 
proposed, ranging from a compact random coil model (Cramer et al., 2001) to variety 
of β-spiral models (Matsushima et al., 1990; Suzuki, 1990; Cagas and Corden, 1995; 
Meinhart and Cramer, 2004). Current evidence suggest that the CTD polypeptide 
adopts secondary structure elements in a portion-wise fashion leading to an overall 
compaction, strongly dependent on the level of phosphorylation. 
 
1.6 CTD phosphorylation and transcriptional regulation 
In the course of the transcription cycle, the CTD undergoes dynamic phosphorylation 
and dephosphorylation (Orphanides and Reinberg, 2002). Transcription initiation 
requires an unphosphorylated CTD, whereas transcription elongation is carried out 
by Pol II with a hyperphosphorylated CTD that binds mRNA processing factors for 
transcription-coupled mRNA maturation. For recycling of Pol II and reinitiation of 
transcription, the CTD must be dephosphorylated. 
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There are five potential phosphorylation sites in a CTD consensus repeat (Y1, S2, 
T4, S5, and S7), out of which only S2 and S5 are being commonly phosphorylated 
(Corden et al., 1985; Zhang and Corden, 1991). These two serine positions are not 
equivalent in function (West and Corden, 1995; Zhang and Corden, 1991) and the 
phosphorylation pattern changes during the transcription cycle due to the 
coordinated action of CTD-kinases and -phosphatases. S5 phosphorylation occurs in 
promoter-proximal regions, and leads to recruitment of the capping enzyme (Cho et 
al., 1997; McCracken et al., 1997b; Ho et al., 1998; Komarnitsky et al., 2000). S2 
phosphorylation predominates in regions that are more distal from the promoter, and 
triggers binding of the 3‘-RNA processing machinery (Komarnitsky et al., 2000; Cho 
et al., 2001). In 2003 Buratowski proposed that a “CTD code” specifies the position of 
Pol II within the transcription cycle. The CTD code would take into account possible 
combinations of different phosphorylation states (S2 and S5) and proline (P3 and P6) 
conformations (cis/trans) within a single consensus peptide and would give rise to 16 
different states of a CTD repeat (Buratowski, 2003).  
 
1.7 CTD kinases 
In humans three cyclin-dependent kinases, CDK7, CDK8, and CDK9, associated 
with cyclins H, C and T, respectively, phosphorylate the CTD (Dynlacht, 1997; 
Bregman et al., 2000; Murray, 2004).  
The CDK7/cyclin H is a part of subcomplex of the ten-subunit general transcription 
factor TFIIH, which phosphorylates the CTD at S5 during transcription initiation (Coin 
and Egly, 1998). In yeast this role is conferred on Kin28, which is essential for 
viability and required for normal transcript levels in vivo (Valay et al., 1995; Holstege 
et al., 1998; Komarnitsky et al., 2000; Schroeder et al., 2000; Liu et al., 2004).  
The CDK8/cyclin C pair (Srb10/Srb11 in yeast) together with MED12 and MED13 
forms a module of the Mediator complex that phosphorylates the CTD at S5 residues 
and is therefore associated with transcription initiation complexes. This module is 
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conserved among eukaryotes, and is a target of signal transduction pathways (Liu et 
al., 2001; Borggrefe et al., 2002; Boube et al., 2002; Samuelsen et al., 2003). The 
CDK8/cyclin C pair is thought to be mainly implicated in transcriptional repression 
(Hengartner et al., 1998). The mode of this repression remains, however, unknown.  
The CDK9/cyclin T pair forms the core of the positive transcription elongation factor 
P-TEFb (Price, 2000) and phosphorylates S2 of the CTD. P-TEFb was isolated by its 
ability to overcome arrest of Pol II complexes during early elongation, a function that 
requires the CTD (Marshall and Price, 1995; Marshall et al., 1996). Ctk1 and Bur1 
are two putative homologs of CDK9 found in yeast (Prelich and Winston, 1993; 
Murray et al., 2001; Prelich, 2002; Guo and Stiller, 2004) thought to phosphorylate 
both CTD and elongation factor Spt5 (Keogh et al., 2003).  
Presently crystal structures are available of free CDK7 (Lolli et al., 2004), cyclin H 
(Andersen et al., 1997) and cyclin C (Hoeppner et al., 2005). Still however the basis 
for specificity of a kinase for the CTD and for recognition of a particular CTD residue 
remains unknown and awaits the structure solution of CDK/CTD complexes.  
 
1.8 CTD phosphatase Ssu72 
The yeast Ssu72 is a highly conserved and essential protein, playing roles in all three 
phases of the transcription cycle. It was initially identified based on genetic and 
physical interactions with the general transcription factor TFIIB (Sun and Hampsey, 
1996; Wu et al., 1999; Pappas and Hampsey, 2000; Dichtl et al., 2002). In addition, it 
is a component of the CPF 3’-end processing machinery and is required for pre-
mRNA and snoRNA 3’-end formation (Gavin et al., 2002; Dichtl et al., 2002; He et al., 
2003; Steinmetz and Brow, 2003; Nedea et al., 2003). 
Primary sequence of Ssu72 contains the CX5RS signature motif indicative of protein 
tyrosine phosphatases (PTPases) (Figure 6A; Meinhart et al., 2003b; Ganem et al., 
2003). Phosphatase activity was confirmed by cleavage of the synthetic substrate p-
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nitrophenyl phosphate (Meinhart et al., 2003; Ganem et al., 2003). In PTPases, the 
conserved cysteine and arginine residues of the signature motif form part of the 
active site (Figure 6A; Ramponi and Stefani, 1997). The cysteine attacks the 
substrate phosphorus atom, leading to formation of a phosphocysteinyl intermediate 
(Figure 6B). The arginine stabilizes the transition state (Burke and Zhang, 1998).  
Figure 6: SSu72 model (A) and proposed mechanism of catalysis (B). (A) Ssu72 has been 
modeled by homology based on the structure of the bovine low-molecular-weight phosphotyrosine 
phosphatase (PDB code 1phr) (Su et al., 1994). Loop regions that are uncertain are shown as dashed 
lines. The detailed view on the right depicts the active-site region (marked by a rectangle in the 
structure on the left). A sulfate ion trapped in the structure is depicted in orange/red. The 
phosphorylated side chain of cysteine residue C12 is shown. Figure was prepared with PyMol 
(www.pymol.org). (B) The reaction mechanism involve the formation of a phosphocysteinyl 
intermediate (Ssu72), followed by recycling of the catalytic side chain with the use of a nucleophilic 
water molecule. Mechanism was drawn with MDL ISIS/Draw. 
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Although there is no apparent sequence homology between Ssu72 and PTPases 
outside the signature motif, secondary structure prediction suggested that Ssu72 
adopts the fold of the low-molecular-weight family of PTPases (Figure 6A; Meinhart 
et al, 2003b; Meinhart et al, 2005). In PTPases, an aspartate in a distant loop serves 
as a general acid/base (Barford et al., 1995; M. Zhang et al., 1998). Ssu72 may also 
contain a somewhat modified aspartate loop that includes two catalytically important 
aspartates instead of one (Meinhart et al., 2003b). This and other distinguishing 
features suggest that Ssu72 is the founding member of a new phosphatase 
subfamily that is related to low-molecular weight PTPases.  
Recently it was demonstrated that Ssu72 is a CTD phosphatase with specificity 
towards S5 phosphorylation (Krishnamurthy et al., 2004). Depletion of Ssu72 in vivo 
results in an increase of S5-phosphorylated Pol II, and Ssu72 dephosphorylates 
recombinant CTD that had been phosphorylated at S5 by TFIIH in vitro. The 
essential role of Ssu72 in 3’-processing does not, however, depend on its 
phosphatase activity.  
 
1.9 CTD phosphatases of the Fcp1 family 
Dephosphorylation of CTD serine residues is catalyzed by the CTD phosphatase 
Fcp1 (Archambault et al., 1997; Archambault et al., 1998; Chambers and Dahmus, 
1994; Chambers and Kane, 1996; Cho et al., 1999; Kobor et al., 1999; Lin et al., 
2002a). Fcp1 is the founding member of a new phosphatase family with no sequence 
similarity to other phosphatases, except for the signature motif DXDX(T/V) that is 
shared within a superfamily of phosphotransferases and -hydrolases (Collet et al., 
1998). The Fcp1 sequence comprises two conserved regions. The N-terminal Fcp1 
homology (FCPH) region includes the DXDX(T/V) signature motif with residues 
important for catalysis. The C-terminal BRCT (breast cancer protein related carboxy-
terminal) domain binds to the phosphorylated CTD (Yu et al., 2003).  
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Fcp1 is conserved throughout eukaryotes and is essential for cell viability. Genome-
wide expression analysis of a temperature-sensitive Fcp1 mutant shows a nearly 
global defect in Pol II transcription (Kobor et al., 1999). In humans, partial deficiency 
of Fcp1 is associated with a strong neurodegenerative disorder known as congenital 
cataracts facial dysmorphism neuropathy syndrome (Varon et al., 2003). 
Dephosphorylation of the Pol II CTD by Fcp1 can facilitate recycling of the 
hyperphosphorylated form of the polymerase for a new round of transcription (Cho et 
al., 1999). Fcp1 dephosphorylates the CTD in solution (Chambers et al., 1995; Cho 
et al., 1999) and when associated with a transcription elongation complex (Cho et al., 
1999; Lehman and Dahmus, 2000). The phosphatase activity of Fcp1 is stimulated 
by the general transcription factor TFIIF, and the general factor TFIIB inhibits this 
stimulation (Chambers et al., 1995). Taken together, Fcp1 is a central regulator of the 
mRNA transcription cycle, but its structure and mechanism remained unclear. 
In higher eukaryotes a second CTD phosphatase was described, the small CTD 
phosphatase Scp1 (Yeo et al., 2003). Scp1 shows homology to the catalytic FCPH 
domain of Fcp1, but lacks the BRCT domain. Scp1 is a transcriptional regulator that 
silences neuronal genes in nonneuronal tissue (Yeo et al., 2005). Plants contain CTD 
phosphatase-like proteins (CPLs), which also comprise a catalytic domain with a 
DXDXT motif, and also lack a BRCT domain (Koiwa et al., 2004). Microsporidian 
parasite Encephalitozoon cuniculi, however, encodes a minimized 411-amino acid 
Fcp1-like protein (EcFcp1), which consists of a DXDXT phosphatase domain and a 
BRCT domain, but lacks the large N- and C-terminal domains found in fungal and 
metazoan Fcp1 enzymes (Hausmann et al., 2004). 
Fcp1 and Scp1 were reported to dephosphorylate S5 and S2 (Table 3; Hausmann 
and Shuman, 2002; Lin et al., 2002a; Yeo et al., 2003). Highly purified Fcp1 was 
recently shown to dephosphorylate S5, but not S2 (Kong et al., 2005). Plant CPLs 
were also shown to specifically dephosphorylate S5 (Koiwa et al., 2004). EcFcp1 
dephosphorylates CTD positions S2 and S5 with similar efficacy in vitro (Hausmann 
et al., 2004). An overview of the CTD phosphatases and their preferential targets is 
given in the Table 3. 
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Table 3: Specificity of CTD phosphatases 
CTD phosphatases S2 dephosphorylation S5 dephosphorylation References 
Fcp1 (S. cerevisiae) +  Cho et al., 2001a 
Fcp1 (S. cerevisiae)  + Kong et al., 2005 
Fcp1 (S. pombe) +  Hausmann and Shuman, 2002 
Fcp1 (H. sapiens) + + Lin et al., 2002a 
EcFcp1  + + Hausmann et al., 2004 
Scp1 (+) + Yeo et al., 2003 
Ssu72  + Krishnamurthy et al., 2004 
CPLs  + Koiwa et al., 2004 
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1.10 Aims of this work 
Several years ago, the first structures of CTD interacting domains (CIDs) were 
brought to scientific attention. These included an N-terminal WW domain of 
Pin1/Ess1 prolyl isomerase (Verdecia et al, 2000), the FF domain in FBP11 (Allen et 
al., 2002) and a domain of the capping enzyme subunit Cgt1 (Fabrega et al., 2003). 
A striking observation was a variety of the emerging CTD-binding folds even though 
they all have the “same” binding partner. However, no structural information was 
available on any of the CTD-modifying enzymes at the time. It was only logical to 
pursue the structure of the Fcp1-family CTD phosphatases, with Fcp1 by then being 
the only reported CTD phosphatase that stands at the center of Pol II recycling. 
Therefore, one aim of this work was to elucidate the mechanism of Pol II 
dephosphorylation by structure-function analysis of Pol II CTD phosphatases. 
Contrary to Fcp1, substantial structural information on portions of human TFIIF was 
already available (Groft et al., 1998; Gaiser et al., 2000; Kamada et al., 2001; 
Kamada et al., 2003; Nguyen et al., 2003a; Nguyen et al, 2003b). However, the 
mode of interaction with Pol II, aside of biochemical data, was not known. The main 
obstacle towards that goal was of technical nature. Yeast TFIIF, unlike other smaller 
general transcription factors, could not be overexpressed in bacteria, and could only 
be purified from yeast in insufficient amounts for crystallographic study. In the course 
of this PhD project, however, the general topology of Pol II-TFIIF complex was 
elucidated by electron microscopy (Chung et al., 2003), a technique that requires far 
less protein material compared to X-ray crystallography. The limitations of this 
technique still do not allow higher resolution studies, and the details of Pol II-TFIIF 
interaction remained unknown. Therefore, the second aim of this work was to 
prepare Pol II-TFIIF complex as a major step towards the structure of the initially 
transcribing complex. 
 
 





# 	




25 
2.1 Bacterial and yeast strains 
 
Table 4: E. coli strains 
Strain Description Source or reference 
XL-1 blue strain recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac[F’ proAB laclqZM15Tn10(Tetr)]  
Stratagene 
BL21-CodonPlus (DE3)-RIL B F- ompT hsdS(rB- mB-) dcm+ Tetr gal (DE3) 
endA Hte [argU ileY leuW Camr] 
Stratagene 
B834 E. coli (DE3) (hsd metB) (Budisa et al., 1995) 
 
Table 5: S. cerevisiae strains 
Strain Description Source or reference 
CB010 MATa pep4::HIS3/prb1::LEU2, prc1::HISG, can1, ade2, 
trp1, ura3, his3, leu2-3 
Edwards et al., 1990 
CB010Rpb4 identical to CB010 except RPB4 deletion Edwards et al., 1990; Fu 
et al., 1999 
CB010Tfg1TAP identical to CB010 except TFG1-TAP::TRP1 K. Sträßer 
CB010Tfg2TAP identical to CB010 except TFG2-TAP::TRP1 K. Sträßer 
DSY5 MATa leu2 trp1 ura3-52 his3 pep4 prb1 Dualsystems Biotech 
DSY5-Int1 MATa leu2 ura3-52 his3 pep4 prb1; TRP1::PADH1-TFG2-
TAP-tADH1::TRP1 
this study 
DSY5-Int2 MATa leu2 his3 pep4 prb1; TRP1::PADH1-TFG2-TAP-
tADH1::TRP1; URA3-52::PADH1-TFG3-tADH1::URA3-52 
this study 
DSY5-Int3 MATa his3 pep4 prb1; TRP1::PADH1-TFG2-TAP-
tADH1::TRP1; URA3-52::PADH1-TFG3-tADH1::URA3-52; 
LEU2::PADH1-TFG1-tADH1::LEU2 
this study 
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2.2 Plasmids  
The pET-21a-d(+) vectors carry an N-terminal T7-Tag sequence plus an optional C-
terminal His-Tag sequence. These vectors differ from pET-24a-d(+) only by their 
selectable marker (ampicillin vs. kanamycin resistance). Target genes are cloned 
under control of strong bacteriophage T7 transcription and translation signals, and 
expression is induced by providing source of T7 RNA polymerase in the host cell. 
Additionally, these vectors possess origin of replication (ori) from pBR322 and f1 
origin.  
YI-type (integrating) E. coli-yeast shuttle vectors permit visual detection of 
recombinants by beta-galactosidase. Multiple cloning site (MCS) stems from pUC19 
with all its 10 unique cloning sites. YIplac vectors contain no replication of origin and 
are used to integrate DNA fragments into the yeast chromosomes by homologous 
recombination. These vectors possess ampicillin bacterial selectable marker, but 
differ in a yeast selectable marker: LEU2 (YIplac128), URA3 (YIplac211) or TRP1 
(YIplac204). The vectors were kindly provided by Marian Kalocay (Jentsch 
Laboratory). 
 
2.3 Media and supplements 
 
Table 6: Supplements and antibiotics 
Supplement or antibiotic Stock solution Applied 
Ampicillin 100 g/L in H2O 100 µg/mL for E. coli; 50 µg/mL for yeast 
Kanamycin 30 g/L in H2O 30 µg/mL 
Tetracycline 12.5 g/L 125 µg/mL 
Chloramphenicol 50 g/L in ethanol 50 µg/mL 
IPTG 1 M in H2O 0.5 mM 
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Table 7: Growth media 
Media Description Source or reference 
LB 1% (w/v) tryptone; 0.5% (w/v) yeast extract; 0.5% (w/v) 
NaCl (+ 1.5 (w/v) agar for selective media plates) 
Sambrook and Russel, 
2001 
SOC 2% tryptone, 0.5% yeast extract,  
10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 20 mM MgSO4, 
20 mM glucose 
Sambrook and Russel, 
2001 
Minimal media 7.5 mM (NH4)2SO4, 8.5 mM NaCl, 55 mM KH2PO4, 100 
mM K2HPO4, 1 mM MgSO4, 20 mM glucose, 1 µg/L trace 
elements (Cu2+, Mn2+, Zn2+, Mo42-), 10 mg/L thiamine, 10 
mg/L biotine, 1 mg/L Ca2+, 1 mg/L Fe2+, 100 mg/L amino 
acids (A, C, D, E, F, G, H, I, K, L, N, P, Q, R, S, T, V, W, 
Y) , 100 mg/L selenomethionine. 
Budisa et al., 1995; 
Meinhart et al., 2003a 
 
YPD 2% (w/v) peptone, 2% (w/v) glucose, 1.48% (w/v) yeast 
extract (+ 1.8% (w/v) agar for selective media plates)  
 
 
2.4 Buffers and solutions 
The following table contains the buffers and solutions used in this work. Buffers for 
specific protein purifications are given separately along with purification protocols. 
 
Table 8. Buffers, dyes and solutions 
SDS-PAGE 
4x stacking gel buffer 0.5 M Tris; 0.4% (w/v) SDS; pH 6.8 (25 °C) 
4x separation gel buffer 3 M Tris; 0.4% (w/v) SDS; pH 8.9 (25 °C) 
electrophoresis buffer 250 mM glycine; 25 mM Tris; 0.1% (w/v) SDS  
5x sample suffer 10% (v/v) glycerol, 50 mM Tris-HCl pH 7.0 (25 °C), 0.1% (w/v) 
bromophenol blue, 0.1% (w/v) lauryl sulfate, 1% (w/v) β-
mercaptoethanol, 14% (w/v) 1,4-dithiothreitol  
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Table 8. (continuation) 
Coomasie staining 
Staining solution 50% (v/v) ethanol, 7% (v/v) acetic acid, 0.125% (w/v) Coomassie 
Brilliant Blue R-250 
Distaining solution 5% (v/v) ethanol, 7.5% (v/v) acetic acid 
Silver staining (Bloom et al., 1987) 
Fixing solution 50% (v/v) ethanol, 12.5% (v/v) acetic acid, 0.01% (w/v) formaldehyde  
Rinse solution I 50% (v/v) ethanol 
Rinse solution II 30% (v/v) ethanol 
Sensitizer 0.2 g/L sodium thiosulfate 
Staining solution 0.1% (w/v) silver nitrate, 0.015% (w/v) formaldehyde 
Developer 6% (w/v) sodium carbonate, 0.01% (w/v) formaldehyde, 0.4 ng/µL 
sodium thiosulfate 
Stop solution 5% (v/v) acetic acid 
Dot blots 
Washing buffer, 1xPBS 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4 
Blocking buffer 5% (w/v) skimmed milk powder in 1xPBS 
Gel electrophoresis of nucleic acids 
Electrophoresis buffer, 1xTBE 8.9 mM Tris, 8.9 mM boric acid, 2 mM EDTA (pH 8.0, 25 °C) 
6x DNA loading dye 1.5 g/L bromophenol blue, 1.5 g/L xylene cyanol, 50% (v/v) glycerol 
2x RNA loading dye (Fermentas) 95% formamide, 0.025% (w/v) SDS, 0.025% (w/v) bromophenol blue, 
0.025% (w/v) xylene cynol, 0.5 mM EDTA 
Sample preparation for Edman sequencing 
Blotting buffer 10% (v/v) methanol in ddH2O 
Rehydration (swelling) buffer 200 mM Tris-HCl pH 8.5 (25 °C), 2% (w/v) SDS 
Buffers for the preparation of chemically competent cells 
TFB-1  30 mM KOAc, 50 mM MnCl
2
, 100 mM RbCl, 10 mM CaCl
2
, 15% (v/v) 
glycerol, pH 5.8 (25 °C) 
TFB-2  10 mM MOPS (pH 7.0, 25 °C), 10 mM RbCl, 75 mM CaCl
2
, 15% (v/v) 
glycerol  
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2.5 Bioinformatic tools 
DNA and protein sequences of yeast proteins were found using Saccharomyces 
Genome Database (http://www.yeastgenome.org). Sequences from other organisms 
were found using NCBI database (http://www.ncbi.nlm.nih.gov/). Homolog searches 
were performed using the NCBI Basic Local Alignment Search Tool (BLAST) server 
(http://www.ncbi.nlm.nih.gov/BLAST/). Multiple sequence alignments were done with 
ClustalW of the program MaC Vector (Accelrys) using default settings and displayed 
by the programs Amas and Alscript (Barton, 1993). 
Secondary structure predictions were performed by the PredictProtein server 
(http://cubic.bioc.columbia.edu/predictprotein). Domain organization was predicted by 
SMART (a Simple Modular Architecture Research Tool) that allows the identification 
and annotation of genetically mobile domains and the analysis of domain 
architectures (http://smart.embl-heidelberg.de/; Schultz et al., 1998).  
A structural homolog search was performed by Dali server (Holm and Sander, 1995; 
http://www.ebi.ac.uk/dali/). Dali compares submitted coordinates of a query protein 
structure against those in the Protein Data Bank (www.rcsb.org). In favorable cases, 
comparing 3D structures may reveal biologically interesting similarities that are not 
detectable by comparing sequences. 
 
2.6 Molecular cloning techniques 
Oligonucleotide design and polymerase chain reaction (PCR). All PCR primers 
for cloning of genes were constructed in a following way. After an overhang of 
several nucleotides (nt) to assure efficiency of cleavage (as recommended by NEB 
catalogue), corresponding restriction sites were introduced followed by 20 to 25 nt of 
the gene sequence of interest. Point mutations were introduced by the PCR overlap 
extension method where two overlapping PCR products are produced carrying the 
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desired mutation in the primer. The resulting products serve as template in a second 
PCR round. 
Template for PCR was S. cerevisiae genomic DNA unless specified otherwise. DNA 
was amplified with Herculase (Stratagene), where higher fidelity was essential, or 
Thermus aquaticus (Taq) DNA polymerase (Fermentas). Generally, 50 µl reactions 
contained 200 µM of each of the four dNTPs, 0.25 µM of forward and reverse primer, 
and approximately 1 ng of template DNA. Additionally, in PCR reactions with 
Herculase, DMSO was varied between 0 and 6%, and with Taq Polymerase, 2 to 4 
mM MgCl2 was added. Thermocycling program contained 30-35 cycles. Times and 
temperatures of denaturation, annealing and elongation were varied to meet the 
special requirements of the polymerase and primer-template pairs used in different 
amplifications. PCR products were subsequently purified with QIAquick PCR 
Purification Kit Protocol (Qiagen).  
Restriction cleavage and ligation. DNA was digested using restriction 
endonucleases (New England Biolabs (NEB)) as recommended by the producer. 
Digested products were purified over an agarose gel using QIAquick Gel Extraction 
Kit Protocol (Qiagen). Ligation of the digested DNA fragments and linearized vectors 
was conducted in 10 µl total volume for one hour at room temperature using T4 
ligase (NEB) and corresponding buffer. In most cases linearized vector was 
incubated with a large (approx. tenfold) excess of insert to improve efficiency of 
ligation.  
Transformation of E. coli and isolation of plasmid DNA. Transformation of 
plasmid DNA into chemically competent E. coli was performed with standard heat 
shock protocols. After thawing a 50 µl aliquot of chemically competent cells on ice, 1 
µl of ligation mixture or purified plasmid DNA was added. Cells were incubated on ice 
for 5 minutes, heat shocked at 42 °C for 45 seconds and incubated on ice for another 
two minutes. Finally, 0.5 mL of LB medium was added to the cells and the mixture 
was incubated for 30 minutes in a 37 °C shaker before plating.  
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E. coli cells from 5 ml of an overnight culture, grown from a single clone, were 
sedimented by centrifugation. Plasmid DNA was extracted from the pellet using the 
QIAprep Spin Miniprep Kit Protocol (Qiagen). Positive clones were verified by 
restriction analysis and DNA sequencing. 
 
2.7 Preparation of competent cells 
200 mL LB media were inoculated with 5 ml of an overnight culture of the desired 
bacterial strain. The cells were grown at 37 °C until an OD600 of 0.4-0.55 was 
reached. After 10 minutes incubation on ice the cells were centrifuged for 10 minutes 
at 5,000 rpm (4 °C). All following steps were performed at 4 °C. The pellet was 
washed with 50 ml of TFB 1 buffer (see chapter 2.4, Table 8) and centrifuged again. 
This pellet was resuspended in 4 ml of TFB 2 buffer (see chapter 2.4, Table 8), 
before aliquoting and plunging into liquid nitrogen.  
 
2.8 Electrophoretic methods 
Electrophoretic separation of DNA. DNA was separated in horizontal 1x TBE, 1% 
agarose (w/v) gels containing ethidium bromide (0.7 µg/mL). Samples were mixed 
with 6x DNA loading dye (see chapter 2.4, Table 8). DNA was visualized using 
standard ultraviolet transilluminator (λ = 254 nm, Eagle Eye, Stratagene).  
Electrophoretic separation of RNA. Electrophoresis was performed in 8% 
polyacrylamide gel (acrylamide:bisacrylamide (19:1)). The gel contained 7M urea and 
10x TBE buffer (see chapter 2.4, Table 8). Immediately before pouring the gel, 0.1% 
APS (v/v) and 0.03% (v/v) TEMED were added. RNA samples were mixed with 2x 
RNA-loading dye (see chapter 2.4, Table 8) and denatured for 2 minutes at 65 °C. 
Electrophoresis was performed in 1x TBE buffer. The RNA was stained with 0.02% 
(v/v) SYBR-Gold Nucleic Acid Stain (Molecular Probes) and visualized at excitation 
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maxima for dye-nucleic acid complexes (λ = 495 nm) with Typhoon Variable Mode 
Imager (GE Healthcare).  
Protein separation by SDS-PAGE. For protein samples glycine-SDS-PAGE with 
12.5%-15% acrylamide gels (acrylamide:bisacrylamide (37.5:1)) (Laemmli, 1970) 
was performed. Gels were routinely stained with Coomassie staining solution. If very 
low amount of protein had to be visualized, silver staining was performed (1 h fixing, 
2x 10 min washing, 1 min sensitizing, 3x 30 sec H2O wash, 20 sec staining, 2x 30 
sec H2O wash, development, reaction stop). 
 
2.9 Preparation of samples for Edman sequencing 
For N-terminal sequencing proteins were separated on SDS-PAGE and stained with 
Coomassie staining solution. The protein band of interest was excised and dried in a 
speed vac. The dried gel piece of gel was rehydrated in the swelling buffer (see 
chapter 2.4, Table 8). Subsequently, 150 µL of distilled water was added to set up a 
concentration gradient together with a small piece of pre-wet (methanol) 
polyvinylidene difluoride (PVDF) membrane (Schleicher & Schuell). Once the solution 
turned blue 10 µL of methanol was added as a catalyst. After 1 to 2 days the 
membrane turned blue, indicating a complete transfer. The membrane was washed 5 
times with 10% methanol. Protein of interest was N-terminally sequenced from the 
dry membrane in a PROCISE 491 sequencer (Applied Biosystems). 
 
2.10 Protein expression in E. coli and selenomethionine 
labeling 
Proteins were expressed recombinantely in E. coli if not stated otherwise. Plasmids 
containing the desired protein variants were transformed into competent E. coli BL21 
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DE3 cells (Stratagene). The cells were grown at 37 °C in LB medium supplemented 
with the antibiotic corresponding to the resistance cassette of the plasmid. Once the 
cells grew to an OD600~0.5 cultures were cooled to 20 °C. Protein expression was 
induced by addition of 0.5 mM IPTG and cells were grown overnight. Cells were 
harvested by centrifugation (5000 rpm, SLC6000 rotor, 30 minutes) at 4 °C, 
resuspended in lysis buffer (see corresponding purifications) and flash frozen in 
liquid nitrogen. Cell pellets were stored at -80 °C. 
Selenomethionine incorporation was essentially performed as described in (Meinhart 
et al., 2003a). Plasmid DNA containing gene of interest was transformed into the 
methionine auxotroph E.coli strain B834 (DE3) (Stratagene). Bacteria were grown in 
LB medium supplemented with the appropriate antibiotic at 37 °C to an OD600~0.5. 
Cells were harvested and resuspended in the same amount of minimal medium 
(Table ) supplemented with selenomethionine (100 mg/l) and antibiotics. Cells were 
grown till the OD600 increased by 0.2 at 37 °C to deplete the medium of any residual 
methionine. Cultures were cooled to 18 °C and protein expression was induced by 
the addition of 0.5 mM IPTG. Protein was expressed overnight.  
 
2.11 Cloning and protein purification of CTD phosphatases 
 
Table 9: Buffers for purification of CTD Phosphatases 
Buffer Description 
Buffer A 300 mM NaCl, 50 mM Tris pH 8.0 (25 °C), 5% glycerol, 10 mM β-
mercaptoethanol 
Buffer B 50 mM NaCl, 50 mM Tris pH 7.5 (25 °C), 5% glycerol, 3 mM DTT 
Buffer C 150 mM NaCl, 10 mM Hepes pH 7.5 (25 °C), 3 mM DTT 
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The gene for human Scp1 (or CTDSP1) was amplified from HUVEC cDNA (provided 
by G. A. Vlastos) and subcloned into pET21b vector (Stratagene). Variants of human 
Scp1 were expressed for 15 h at 20 °C in E. coli BL21 (DE3) RIL (Stratagene). Cells 
were harvested by centrifugation and resuspended in buffer A (Table 9). Cells were 
lyzed by sonication. After centrifugation, the supernatant was loaded onto a 2 mL Ni-
NTA column (Qiagen), equilibrated with buffer A. After washing with 10 mL of buffer 
A, bound protein was eluted with buffer A containing 200 mM imidazole, and in the 
case of full-length Scp1 was further purified by anion exchange chromatography 
(MonoQ, GE Healthcare). The column was equilibrated with buffer B (Table 9), and 
the protein was eluted with a gradient of 10 column volumes from 50 mM to 1 M 
NaCl. After concentration, the sample was applied to a Superose-12 HR gel filtration 
column (GE Healthcare) equilibrated with buffer C (Table 9). Pooled peak fractions 
were concentrated for crystallization to 20 mg mL-1. Variants of Saccharomyces 
cerevisiae Fcp1 were obtained by PCR-amplification of the corresponding regions in 
the gene from yeast genomic DNA and were subcloned into pET21b (S. Heilmeier). 
Expression and purification of variant Fcp1c (residues 168-606) was essentially as 
for Scp1. The variant Scp1∆N comprising residues 77-261, as well as the active site 
mutants (D96N, D96A, D98N, T152S, T152V, T152A, K190A and N207D), with a C-
terminal HisTag were subcloned into pET21b (Stratagene), expressed in E.coli, and 
purified as above, but without the anion exchange step. For MAD phasing, the 
Scp1∆N mutant L165M/L205M, which contains two additional methionines at 
positions of conserved hydrophobic residues, was constructed with the PCR overlap 
extension method and selenomethionine was incorporated as described in chapter 
2.10. 
 
2.12 Limited Proteolysis 
For chymotrypsin and trypsin treatment 1 µg of corresponding protease was added to 
200 µg of purified protein. Digests were done in the buffers used for gel filtration and 
supplemented with CaCl2 to a final concentration of 1 mM. The reaction mixture was 
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incubated at 37 °C for 1, 2, 3, 10, 30, and 60 minutes. The reactions were stopped by 
the addition of 5x sample buffer (see chapter 2.4, Table 8 ) and were heated to 95 °C 
for 5 minutes. 
For proteinase K treatment 1 µl of dilutions of proteinase K (400 ng/µL, 40 ng/µL, 4 
ng/µL, and 0.4 ng/µL) were added to the protein samples. The mixtures were 
incubated on ice for 1 h. The reactions were stopped by the addition of sample buffer 
and boiled as above. All samples were analyzed by SDS-PAGE. Bands of interest 
were passively transferred to PVDF membrane and analyzed by Edman sequencing 
as described in chapter 2.9. 
 
2.13 Crystallization and structure determination 
Samples were crystallized at 20 °C with the hanging drop method, using as reservoir 
solution 20-30% PEG 3300 or PEG 6000 or PEG 8000, 200 mM NH4OAc, 100 mM 
citrate buffer pH 5.6, 5 mM DTT. The thin plate-like crystals grew to a maximum size 
of 400x150x5 µm. To the drops containing crystals, 100 µL cryo solution (25% PEG 
3300 or PEG 6000 or PEG 8000, 15% PEG 400, 200 mM NH4OAc, 100 mM citrate 
buffer pH 5.6, 5 mM DTT) were added, and after 10 min crystals were flash-cooled 
by plunging into liquid nitrogen. A MAD experiment was performed on crystals from 
the selenomethionine-labeled L165M/L205M double mutant at the Swiss Light 
Source (see chapter 3.1.1, Table 18). Data were processed with DENZO and 
SCALEPACK (Mutant L165M/L205M SeMet MAD data, Otwinowski and Minor, 
1996), or with XDS (wild type beryllofluoride data, Kabsch, 1993). The crystals 
belong to space group P21212. Program SOLVE (Terwilliger, 2002) was used for 
detection of 5 selenium sites (M76, M142, M165, M205, M229) and for MAD phasing 
(Z-score=43.3, FOM=0.62). Phases were further improved by SHARP (La Fortelle 
and Bricogne, 1997). The resulting electron density map allowed building of an 
atomic model, which was refined with CNS (Brunger et al., 1998) against the remote 
wavelength dataset to 2.3 Å resolution (see chapter 3.1.1, Table 18). To trap the 
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beryllofluoride inhibitor in the active site, preformed wild type crystals were soaked 
with 5 mM BeCl2/24 mM NaF for 10 min before flash-cooling and data collection at 
the Swiss Light Source. After phasing with the refined model, clear difference density 
at residue D96 indicated the presence of beryllofluoride. Except for minor changes in 
the water structure in the active site, the structure is essentially identical and was 
refined to 2.1 Å resolution (see chapter 3.1.1, Table 18). In both refined structures, 
99% of the residues fall in allowed and additionally allowed regions of the 
Ramachandran plot, and none of the residues are in disallowed regions. 
 
2.14 Phosphatase kinetics and inhibitor studies 
A discontinuous indirect spectrophotometric assay for p-nitrophenol (pNP) was used 
to determine enzymatic parameters. Reactions were carried out at 37 °C in a total 
volume of 100 µL and contained 50 mM Tris-acetate pH 5.5, 10 mM MgCl2, 0.19 µM 
Scp1∆N (or 0.1 µM Fcp1c) and varying concentrations of p-nitrophenylphosphate 
(pNPP). Reactions were initiated by addition of the enzyme and quenched 
subsequently in 30 s or 60 s increments by adding 900 µL of 1 M sodium carbonate. 
Prior to enzyme addition, reaction mixtures were incubated for 5 min to allow for 
temperature equilibration. Rates of pNP release were determined by monitoring 
absorbance at 405 nm and interpolating the value to a pNP standard curve. A 
minimum of five colinear data points for each substrate concentration were used to 
carry out linear fits to obtain the initial reaction velocity (not shown). Velocities were 
plotted against substrate concentration to obtain standard Michaelis-Menten curves 
(not shown). To derive KM and kcat, velocities were plotted against velocity divided by 
substrate concentration according to Eadie-Hofstee (see Figure  11A). To obtain the 
molar extinction coefficient ε, a standard curve was determined by measuring the 
absorbance at 405 nm of known pNP concentrations (Sigma) in the assay mixture. 
This plot was linear between 5 and 150 mM pNP, and yielded ε = 18,300 (M x cm)-1. 
To study the effect of various inhibitors on phosphatase reactions, 100 µL reaction 
mixtures containing 10 mM pNPP and additionally different phosphatase inhibitors 
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were incubated for 30 min at 37 °C, quenched with 900 µL 1 M sodium carbonate, 
and the amount of released pNP was determined by measuring the absorbance at 
405 nm with the use of the pNP standard curve (compare Fig. 11B).  
 
2.15 Activity assay with active site mutants 
To study the effect of individual active site amino acid replacements on phosphatase 
reactions, 100 µL reaction mixtures containing 10 mM pNPP, 50 mM Tris-acetate pH 
5.5, 10 mM MgCl2, and additionally 0.1 µM of different active site mutants (D96N, 
D96A, D98N, T152S, T152V, T152A, K190A and N207D) were incubated for 30 min 
at 37 °C. The reactions were quenched with 900 µL 1 M sodium carbonate, and the 
amount of released pNP was determined by measuring the absorbance at 405 nm.  
 
2.16 Purification of Pol II core enzyme 
Table 10: Buffers for Pol II core enzyme purification 
Buffer Description 
3x freezing buffer 150 mM Tris-HCl, pH 7.9 (4 °C), 3 mM EDTA, 30% glycerol, 30 µM ZnCl2, 3% DMSO, 
30 mM DTT, 3x protease inhibitor mix 
100x protease 
inhibitor mix (p.i.) 
1.42 mg leupeptin, 6.85 mg pepstatin A, 850 mg PMSF, 1650 mg benzamidine, dry 
ethanol to 50 mL, stored at -20 °C; added immediately before use 
1x HSB150 50 mM Tris-HCl, pH 7.9 (4 °C), 150 mM KCl, 1 mM EDTA, 10% glycerol, 10 µM ZnCl2, 
10 mM DTT, 1x protease inhibitor mix 
1x HSB600 50 mM Tris-HCl, pH 7.9 (4 °C), 600 mM KCl, 1 mM EDTA, 10% glycerol, 10 µM ZnCl2, 
10 mM DTT, 1x protease inhibitor mix 
1x TEZ 50 mM Tris-HCl, pH 7.5 (20 °C), 1 mM EDTA, 10 µM ZnCl2, 5 mM DTT, 1x protease 
inhibitor mix 
UnoQ buffer 50 mM Tris-HCl, pH 7.5 (20 °C), 1 mM EDTA, 10 µM ZnCl2, 10% (v/v) glycerol, 10 mM 
DTT, no protease inhibitors 
Pol II buffer 5 mM Hepes pH 7.3 (20 °C), 40 mM ammonium sulfate, 10 µM ZnCl2, 10 mM DTT 
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Pol II was essentially purified as described in (Armache et al., 2003). For three bead-
beaters (BioSpec), up to 600 mL of cell suspension were thawed in warm water. 
Each bead-beater was filled with 200 mL of borosilicate glass beads (0.45-0.50 mm 
diameter), 1 mL of protease inhibitor mix (Table 10) and 200 mL of the cell 
suspension. HSB150 (Table 10) was added to fill the bead-beater completely, taking 
care to avoid any remaining air bubbles. Lysis was achieved within one hour of bead-
beating (30 s on/90 s off) while the beater chambers were submersed in a salt/ice 
mixture. Glass beads were removed by filtration through a mesh funnel. The beads 
were washed with HSB150 until the flowthrough was clear. The lysate was cleared 
by two rounds of centrifugation (30 minutes at 12000 rpm in a GS3 rotor). Lipids 
were then removed by filtration of the supernatant through two layers of paper filter 
discs underneath a dressing cloth. 
The cleared lysate was applied onto a 250 mL of Heparin Sepharose 6 FF (GE 
Healthcare) column, pre-equilibrated with 750 mL of HSB150. Elution was 
accomplished with 500 mL of HSB600 (Table 10). Proteins in the eluate were 
precipitated by adding 291 g of fine-ground ammonium sulfate per liter of eluate 
(~50% saturation), followed by 20 minutes of stirring at 4 °C and centrifugation (45 
minutes at 12000 rpm in a GS3 rotor). The pellet was stored over night at 4 °C. The 
heparin column was restored by washing with 1 L of 6 M urea, followed by water, and 
stored in 5 mM potassium acetate and 20 % (v/v) ethanol.  
The ammonium sulfate pellet was dissolved in 50 mL of TEZ buffer (Table 10). More 
TEZ was added to set the conductivity below the conductivity of TEZ containing 
additionally 400 mM ammonium sulfate (TEZ400). This sample was loaded by gravity 
flow onto the immunoaffinity column with coupled 8WG16 monoclonal antibodies 
(NeoClone, Madison/USA), specific for the unphosphorylated CTD of Pol II and 
optimized to release Pol II upon treatment with glycerol or ethylene glycol at room 
temperature (“polyol responsive antibody“, Thompson and Burgess, 1996). The 
column was pre-equilibrated with 20 mL of TEZ containing 250 mM ammonium 
sulfate (TEZ250). The flowthrough was re-loaded to yield 10-20% more Pol II. The 
column was brought to room temperature, washed with 25 mL of TEZ250 at room 


39 
temperature and Pol II was eluted in 1 mL fractions with TEZ500 containing 
additionally 50% (v/v) glycerol (ca. 15 mL). Directly afterwards, the column was 
washed with 5 mL of TEZ500 containing 70% (v/v) ethylene glycol but no DTT, and 
re-equilibrated with 25 mL of TEZ250 containing 0.02% sodium azide. Protein 
containing fractions were diluted six-fold and loaded onto a UnoQ column (BioRad, 
column volume 1.35 mL), pre-equilibrated with UnoQ buffer (Table 10) containing 60 
mM ammonium sulfate (UnoQ-A). The column was washed with 3 column volumes of 
this buffer, and Pol II was eluted with a linear gradient over 10 column volumes from 
0-50% buffer UnoQ containing 1 M ammonium sulfate (UnoQ-B). Pol II elutes at 
about 25% buffer UnoQ-B. The column was restored by washing with 5 column 
volumes of UnoQ-B. 
Peak fractions were pooled and split into aliquots of 500 µg Pol II. The aliquots were 
mixed 1:1 with ammonium sulfate solution saturated at room-temperature, incubated 
for ~1 hour at 4 °C and centrifuged for 30 minutes at 4 °C in a table-top centrifuge at 
14000 rpm. Most of the supernatant was decanted so that the pellet was still covered 
with supernatant, before it was shock-frozen in liquid nitrogen and stored at -80 °C. 
From 600 g yeast pellet, a yield of 5-8 mg of highly purified Pol II can be expected. 
 
2.17 Purification of Rpb4/7 subcomplex 
 
Table 11: Buffers for Rpb4/7 purification 
Buffer Description 
Buffer A 150 mM NaCl, 50 mM Tris pH 7.5 (25 °C), 5% glycerol, 10 mM β-
mercaptoethanol, protease inhibitors 
Buffer B 50 mM Tris pH 7.5 (25 °C), 1 mM EDTA, 5 mM DTT 
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Recombinant yeast Rpb4/7 was cloned and overexpressed in E. coli using a vector 
having both subunits under the control of separate T7 promoters (Sakurai et al., 
1999). Cells from 2 L of culture were resuspended in buffer A (Table 11) and lyzed 
by sonication. The lysate was cleared by centrifugation (30 minutes at 15000 rpm in 
a SS34 rotor) and applied onto a Ni-NTA column (Qiagen; 1 mL column volume). The 
column was washed with 5 mL of buffer A containing additionally 20 mM imidazole. 
Elution was performed with 6 mL of buffer A containing 200 mM imidazole. Peak 
fractions were pooled, diluted 1:3 with buffer B (Table 11) and applied on a 
ResourceQ column (GE Healthcare, 6 mL column volume), pre-equilibrated in buffer 
B. Rpb4/7 subcomplex was eluted with a linear gradient from 0-1 M NaCl in buffer B. 
Peak fractions were concentrated and applied on a Superose 12 HR10/30 gel 
filtration column (GE Healthcare), pre-equilibrated in Pol II buffer (see chapter 2.16, 
Table 10). The purified Rpb4/7 heterodimer was concentrated to 10 mg/mL and 
aliquots were stored at -80 °C. 
 
2.18 Reconstitution of a Pol II-Fcp1 complex 
For reconstitution of a Pol II-Fcp1 complex, a total of 0.5 mg of 10-subunit core Pol II 
in Pol II buffer (see chapter 2.16, Table 10) was incubated with a 5-fold excess of 
recombinant Rpb4/7 subcomplex at 20 °C for 45 min, followed by a 5-fold excess of 
Fcp1 with respect to Rpb4/7 and an additional incubation of 2 h. The Pol II-Fcp1 
complex was separated from free Rpb4/7 and Fcp1 by gel filtration on a Superose 6 
column (GE Healthcare). 
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2.19 Purification of TFIIF variants expressed in E. coli  
Table 12: Overview of TFIIF expression trials in E. coli. Tfg1 and Tfg2 were cloned into pET21b 
vector and Tfg3 into pET24d. (“::” indicates deletion) 
Bicistronic expression of Tfg1-His and Tfg2 (+ co-transformation of Tfg3) 
Tfg1 
(735 aa, 82.2 kDa) 
Tfg2 
(400 aa, 46.6 kDa) 
Tfg3 
(244 aa, 27.4 kDa) 
Outcome 
Amino 
acid 
MW 
(kDa) 
Amino 
acid 
MW 
(kDa) 
Amino 
acid 
MW 
(kDa) 
  
88-345 28.1 46-273 27.5 -   Tfg1(+), Tfg2(-) 
56-661 
(F1r1) 
67.8 46-273 27.5 -   No overexpression 
56-510 
(F1r2) 
50.8 46-273 27.5 -   No overexpression 
56-442 
(F1r3) 
43 46-273 27.5 -   No overexpression 
234-661 
(F2r1) 
48 46-273 27.5 -   No overexpression 
234-442 
(F2r3) 
23.1 46-273 27.5 -   Tfg1(+poor exp., Edman), Tfg2(-) 
56-661 
(F1r1) 
67.8 46-144:: 
192-273 
21.2 -   No overexpression 
56-510 
(F1r2) 
50.8 46-144:: 
192-273 
21.2 -   Tfg1(+), Tfg2(+) 
56-442 
(F1r3) 
43 46-144:: 
192-273 
21.2 -   Tfg1(+), Tfg2(+) 
234-661 
(F2r1) 
48 46-144:: 
192-273 
21.2 -   Poor expression 
234-442 
(F2r2) 
31 46-144:: 
192-273 
21.2 -  Tfg1(+), Tfg2(+, Edman) 
234-442 
(F2r3) 
23.1 46-144:: 
192-273 
21.2 -   Tfg1(+), Tfg2(+, Edman) 
234-735 
(F2r0) 
56.3 46-144:: 
192-273 
21.2 -   Tfg1(+), Tfg2(-) 
56-735 
(F1r0) 
56.3 46-144:: 
192-273 
21.2 + 27.4 Edman:Tfg1(+), Tfg2(-), Tfg3(+) 
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Expression of Tfg2-ht as single subunit 
Amino acids MW (kDa) Conclusion 
46-144::192-370 (FR1,Dloop) 32.6 Soluble 
46-370 (FR1) 38.9 Soluble 
209-370 (F1R1) 18.8 Soluble 
Expression of Tfg1 and Tfg2, each under the control of separate T7 promoter (+co-transformation with Tfg3) 
Tfg1 
(735 aa, 82.2 kDa) 
Tfg2 
(400 aa, 46.6 kDa) 
Tfg3 
(244 aa, 27.4 kDa) 
Conclusion 
Amino 
acids 
MW 
(kDa) 
Amino acids MW 
(kDa) 
Amino 
acids 
MW 
(kDa) 
  
234-735 
(F2r0)His 
56.3 46-370 (FR1) 38.9 -  Tfg1(+), Tfg2(-) 
306-661 
(F3r0)His 
40.7 46-370 (FR1) 38.9 -   Tfg1(+), Tfg2(-) 
234-735 
(F2r0)His 
56.3 46-144::192-370 
(FR1,Dloop) 
32.6 -   Tfg1(+), Tfg2(-) 
306-661 
(F3r0)His 
40.7 46-144::192-370 
(FR1,Dloop) 
32.6 -   Tfg1(+poor exp.), 2(-) 
234-735 
(F2r0) 
56.3 46-370 (FR1)His 38.9 -   No overexpression 
306-661 
(F3r0) 
40.7 46-370 (FR1)His 38.9 -   No overexpression  
234-735 
(F2r0)His 
56.3 46-370 (FR1) 38.9 + 27.4 Tfg1(+), Tfg2(-,MALDI), Tfg3(+) 
306-661 
(F3r0)ht 
40.7 46-370 (FR1) 38.9 + 27.4 Tfg1(+), Tfg2(-), Tfg3(+) 
234-735 
(F2r0)His 
56.3 46-144::192-370 
(FR1,Dloop) 
32.6 + 27.4 Tfg1(+), Tfg2(-), Tfg3(+) 
306-661 
(F3r0)His 
40.7 46-144::192-370 
(FR1,Dloop) 
32.6 + 27.4 Tfg1(+), Tfg2(-), Tfg3(+) 
Table 12 (continuation) 
56-735 
(F1r0)* 
56.3 46-144:: 
192-273 
21.2 + 27.4 Tfg1(+), Tfg2(-), Tfg3(+) 
234-735 
(F2r0)* 
56.3 46-144:: 
192-273 
21.2 + 27.4 Tfg1(+), Tfg2(Edman), 3(+) 
56-735 
(F1r0)* 
56.3 46-273 27.5 + 27.4 Tfg1(+), Tfg2(?), Tfg3(+) 
234-735 
(F2r0)* 
56.3 46-273 27.5 + 27.4 Tfg1(+), Tfg2(?), Tfg3(+) 
56-510 
(F1r2)* 
50.8 46-144:: 
192-273 
21.2 + 27.4  Tfg1(+), Tfg2(?), Tfg3(+) 
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Table 12 (continuation) 
234-735 
(F2r0)His 
56.3 46-370 (FR1)His 38.9 + 27.4 Tfg1(+), Tfg2(-), Tfg3(+) 
306-661 
(F3r0)His 
40.7 46-370 (FR1)His 38.9 + 27.4 Tfg1(+), Tfg2(-), Tfg3(+) 
 
 
Table 13: Buffers for purification of TFIIF variants expressed in E. coli 
Buffer Description 
Buffer A 150 mM NaCl, 50 mM Tris pH 8.0 (25 °C), 10 mM β-mercaptoethanol 
Buffer B 20 mM Hepes pH 7.0 (25 °C), 3 mM DTT 
Buffer C 150 mM NaCl, 20 mM Hepes pH 7.5 (25 °C), 3 mM DTT 
 
Different recombinant yeast TFIIF variants were cloned and over expressed in E. coli 
(see Table 12). Cells from 2 L of culture were resuspended in buffer A (Table 13) and 
lyzed by sonication. The lysate was cleared by centrifugation (30 minutes at 15000 
rpm in a SS34 rotor) and applied onto a Ni-NTA column (Qiagen; 1 mL column 
volume). The column was washed with 5 mL of buffer A containing additionally 10 
mM imidazole. Elution was performed with 3 mL of buffer A containing 200 mM 
imidazole. Peak fractions were pooled, diluted 1:3 with buffer B (Table 13) and 
applied on a Heparin column (GE Healthcare, 1 mL column volume), pre-equilibrated 
in buffer B containing 50 mM NaCl. TFIIF variants were eluted with a linear gradient 
from 50 mM-1 M NaCl in buffer B. Peak fractions were concentrated and applied on a 
Superose 6 HR10/30 gel filtration column (GE Healthcare), pre-equilibrated in buffer 
C (Table 13).  
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2.20 Generation of a yeast strain overexpressing TFIIF 
An overexpression cassette containing ADH1 promoter, multiple cloning site (MCS) 
and ADH1 terminator sequence was subcloned into E. coli-yeast shuttle integrative 
(YIplac) vectors (YIplac128, YIplac204 and YIplac211) at EcoRI and HindIII 
restriction sites (see chapter 3.2.3, Figure 17). These vectors contain markers 
(TRP1, URA2 and LEU2) which complement specific auxotrophic mutations in yeast 
DSY5 strain (Dualsystems Biotech) and allow selection of transformants containing 
the desired plasmids. Genes coding for Tfg1, Tfg2 carrying a C-terminal TAP-tag, 
and Tfg3, amplified from yeast genomic DNA, were subcloned into XbaI and SalI 
sites within the MCS of the overexpression cassette in YIplac128, YIplac204 and 
YIplac211, respectively. The YIplac204 plasmid carrying a gene for Tfg2-TAP under 
the control of the ADH1 promoter was linearized with EcoRV restriction 
endonuclease within the TRP1 gene and used for transformation of DSY5 yeast 
strain (Dualsystems Biotech). The linear ends are recombinogenic and direct 
integration to the site in the yeast genome that is homologous to these ends. A 
resulting yeast strain (DSY5-Int1) was recovered on a YPD selective plate lacking 
tryptophan. From a single clone, a yeast culture was grown and centrifuged. 
Resulting yeast pellet served for the transformation with YIplac211 plasmid carrying a 
gene for Tfg3 under the control of the ADH1 promoter and linearized with StuI 
restriction enzyme within the URA3 gene. A resulting yeast strain (DSY5-Int2) was 
recovered on a YPD selective plate lacking uracil and used as described for the 
transformation with the YIplac128 plasmid carrying a gene for Tfg1 under the control 
of the ADH1 promoter and linearized with EcoRV restriction enzyme within the LEU2 
gene. Finally, resulting yeast strain (DSY5-Int3), containing all three subunits of 
TFIIF, each under the control of the ADH1 promoter, was recovered on a YPD 
selective plate lacking leucine. 
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2.21 Isolation of genomic DNA from yeast 
2-5 mL of a dense yeast culture was centrifuged. The pellets were resuspended in 
200 µL of the buffer containing 100 mM Tris-HCl pH 8.0 (25 °C), 100 mM NaCl, 1 
mM EDTA, 1% (w/v) SDS, 2% Triton X-100. 200 µL of phenol-chloroform-isoamyl 
mixture (Roth) was added and 300 mg of glass beads. The suspension was agitated 
in the vibraxer at maximum speed for 5 minutes. 200 µL of 1x TE buffer (see chapter 
2.22, Table 14) was added and the suspension was centrifuged for 5 minutes at 
14000 rpm. Upper layer was extracted, followed by chloroform wash and re-
extraction. The genomic DNA in the upper phase was precipitated with 1 mL of pure 
ethanol followed by 1 min centrifugation. Additional wash with 70% ethanol was 
performed. The pellets were air-dried and dissolved in 100 µL of TE buffer, 
containing RNase. 
 
2.22 Yeast transformation 
Yeast transformation was performed according to the lithium acetate-PEG procedure 
(Ito et al., 1983). 50 mL of yeast culture (adequate for 5-6 transformations) were 
grown to OD600 between 0.5 and 0.8. The culture was centrifuged for 5 minutes at 
3600 rpm. The pellets were washed with 10 mL water and resuspended in 500 µL of 
solution I (Table 14). Resulting suspension was centrifuged for 3 minutes at 3600 
rpm. The pellet was resuspended in 250 µL of solution I. For each transformation 50 
µL of the cell suspension was mixed with 1-4 µg (3 µL) of the linearized DNA, 10 µg 
of carrier DNA (DNA from salmon testes, Sigma) and 300 µL solution II (Table 14). 
The mixture was incubated at room temperature for 30 minutes. Subsequently, a 
heat shock was performed for 10 minutes at 42 °C followed by 3 minute incubation 
on ice. The cells were washed twice with water, centrifuged for 3 minutes at 3600 
rpm. Resulting pellet was resuspended in 500 µL of water and 100 µL was spread on 
a selective media plate. 
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Table 14: Buffers and solutions for yeast transformation 
Buffer Description 
10x TE 100 mM Tris pH 7.5 (25 °C), 10 mM EDTA 
10x LiOAc 1 M LiOAc pH adjusted to 7.5 (25 °C) 
Solution I 0.5 mL 10x TE, 0.5 mL 10x LiOAc, 4 mL H2O (sterile filtered) 
Solution II 0.5 mL 10x TE, 0.5 mL 10x LiOAc, 4 mL 50% PEG3350 (sterile filtered) 
Selective plate media, 
pH 5.5 (25 °C) 
0.67% (w/v) yeast nitrogen base (Formedia), 2% (w/v) glucose, 20 mg/L 
arginine (HCl), 80 mg/L aspartate, 100 mg/L glutamate, 50 mg/L 
isoleucine, 50 mg/L lysine (HCl), 20 mg/L methionine, 50 mg/L 
phenylalanine, 375 mg/L serine, 100 mg/L threonine, 50 mg/L tyrosine, 
140 mg/L valine, 20 mg/L adenine, 20 mg/L histidine, 100 mg/L leucine, 
40 mg/L tryptophan, 20 mg/L uracil 
YPD-Trp- Selective plate media minus tryptophan 
YPD-Leu- Selective plate media minus leucine 
YPD-Ura- Selective plate media minus uracil 
 
 
2.23 Small-scale Pol II-TFIIF tandem affinity purification 
(TAP) 
Yeast pellet from 2 L of culture was thawed and filled with the lysis buffer (Tris 25 
mM pH 7.9 (25 °C), 200 mM potassium acetate, 0.1% Igepal CA-630 (Sigma), 5 mM 
EDTA, 5% glycerol) to a total volume of 25 mL. The same volume of borosilicate 
beads, followed by the suspension, was added to a cold lysis container. Lysis was 
performed in bead-beater (Planeten-Monomühle, Fritsch) (2x 4 min on/1 min off). 
Borosilicate beads were removed over a 50 mL syringe with an inserted metal filter. 
The beads were washed by adding 10 mL of lysis buffer. The lysate was centrifuged 
at 4000 rpm for 10 minutes (4 °C). Supernatant was ultracentrifuged for 1 hour at 
40000 rpm (TI45 rotor). The upper phase containing lipid flakes was removed with 
water pump. Glycerol was added to the clear lysate to a total concentration of 5% 
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prior to freezing. The clear lysate was submitted to fractional ammonium sulfate 
precipitation and fractions were analyzed by dot blot assay. Pol II-TFIIF complex 
completely precipitated at 45% ammonium sulfate saturation, the pellet was 
dissolved and incubated with 0.4 mL of pre-washed IgG slurry (GE Healthcare) for 1 
hour at 4 °C. Following centrifugation (1800 rpm, 3 minutes), supernatant was 
removed and beads were thoroughly washed with 10 mL of lysis buffer. 150 µL of 
lysis buffer and 4 µg of TEV protease were added to the IgG beads. Subsequently, 
suspension was incubated for 1 hour at 20 °C. The protein was recovered and either 
loaded on the SDS-gel or loaded on the Superose 6 gel filtration column (GE 
Healthcare) and finally precipitated with trichloroacetic acid. 
 
2.24 Dot blot assay 
Dilution series of early steps of the TAP-purification were prepared in 96-well plates. 
Following transfer from a 96-well plate to a prewashed PVDF membrane (Schleicher 
& Schuell) with a 96-well vacuum dot-blotter (Schleicher & Schuell), the membrane 
was washed with 1x PBS buffer (see chapter 2.4, Table 8), blocked with 5%-milk 
powder solution (w/v), and subjected to a one-step immunoaffinity procedure with a 
peroxidase-anti-peroxidase conjugate (1.2 µg Ab/mL, Sigma). Bound IgG was 
detected by chemiluminescence (ECL, GE Healthcare). The detection limit of this 
method (1 fmol of protein) allows the quantization of proteins present at very low 
levels and processing of many samples rapidly and in parallel (Borgreffe et al., 
2001).  
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2.25 Large-scale isolation of Pol II-TFIIF complex from 
yeast 
 
2.25.1 Yeast fermentation 
Pol II-TFIIF complex was isolated from the Saccharomyces cerevisiae DSY5-Int3 
strain (MATa his3 pep4 prb1; TRP1::PADH1-TFG2-TAP-tADH1::TRP1; URA3-52::PADH1-
TFG3-tADH1::URA3-52; LEU2::PADH1-TFG1-tADH1::LEU2), produced during course of 
this work (see chapter 2.20). This strain carries three TFIIF subunits, each under the 
control of the ADH1 promoter. Doubling time of DSY5-Int3 yeast strain is roughly 1h 
45 min. 
A fermenter (ABEC, Infors) of a nominal volume of 200 L was available for producing 
of up to 1.1 kg of a yeast pellet per batch. Table 15 shows the media composition 
and the culture parameters used for the fermentation of yeast. 
 
Table 15: Conditions for the fermentation of yeast 
YPD media 4 kg peptone 
 4 kg glucose 
 3 kg yeast extract 
 195 L water 
antibiotics1 10 g ampicillin 
 2 g tetracycline 
typical inoculate volume 6-7 L shaker culture, OD600 ~ 3 
air flow 20 L/min 
stirrer speed 220 rpm 
pH 6.9 (30 °C) 
typical growth time 8-10 hours 
                                             1added after sterilization, prior to inoculation 


49 
2.25.2 Harvesting and storage of yeast 
Yeast was harvested at OD600~3.0. Cells were pelleted by centrifugation flow 
centrifuge (Padberg Z4IG, 20000 rpm). From 200 liters of yeast culture 1.1-1.3 kg of 
the yeast cell pellet could be obtained. The cell pellet was resuspended in 350 mL of 
buffer A (50 mM Tris, 200 mM KOAc, 1 mM EDTA, 5% glycerol, 0,18 mM dodecyl-
beta-D-maltosid, 0.5 mM DTT, 1x p.i. mix, pH adjusted to 6.9 at 25 °C) per kg cells. 
Resuspended cells were shock-frozen as 200 mL aliquots in liquid nitrogen and 
stored at -80 °C. 
 
2.25.3 Large-scale purification of the Pol II-TFIIF complex 
For three bead-beaters (BioSpec), up to 750 mL of cell suspension (corresponding to 
100 L of yeast culture) were thawed in warm water. Each bead-beater was filled with 
200 mL of borosilicate glass beads (0.45-0.50 mm diameter), 1 mL of protease 
inhibitor mix and ~250 mL of the cell suspension. Buffer A (see 2.25.2) was added to 
fill the bead-beater completely, taking care to avoid any remaining air bubbles. Lysis 
was achieved within one hour of bead-beating (30 s on/90 s off) while the beater 
chambers were submersed in a salt/ice mixture. Glass beads were removed by 
filtration through a mesh funnel. The beads were washed with buffer A until the 
flowthrough was clear. The volumes were kept as small as possible.  
The lysate was somewhat clarified by centrifugation (30 min at 6000 rpm, SLC6000) 
or alternatively (12000 rpm, 2 x 30 min, GS3 rotor). Lipids were then removed by 
filtration of the supernatant through two layers of paper filter discs underneath a 
cheese cloth. The lysate was further centrifuged for additional 1 hr at 12000 rpm 
(SLA1000 rotor) and 1 hr at 15000 rpm (SS34 rotor). Consequential rounds of 
centrifugation can be replaced with 1 hr ultracentrifugation (40000 rpm, TI45 rotor). 
IgG beads were washed three times with buffer A with no protease inhibitors and 
recovered by centrifugation at 1800 rpm. The clear lysate was divided into 3 batches 
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containing 5 mL of IgG beads and incubated overnight at 4 °C. The IgG beads were 
recovered by centrifugation and transferred into 5 Mobicol columns (5 mL, MoBiTec), 
followed by an intensive wash with Buffer A. To each Mobicol, 2 mL of buffer A 
(without protease inhibitors) and 25 µg of TEV protease were added and incubated 
on a rotating wheel (4 hr, 20 °C). Mobicols were eluted by gravity flow, and 
subsequently centrifuged to collect residual eluate. The elution fractions were 
concentrated at 4000 rcf in the Amicon Ultra Centrifugal Filter Devices (15 mL, 100 
kDa cut-off, Millipore) to the volume of 2 mL (4000 rcf). Concentration was 
accompanied by significant protein precipitation. Concentrated eluate was loaded on 
a Superose 6 gel filtration column (GE Healthcare) previously equilibrated with buffer 
A. The fractions were collected and checked by SDS-electrophoresis. 
The peak fractions containing Pol II-TFIIF stoichiometric complex were pooled and 
concentrated using small centricons (4 mL, 100 kDa cut-off, Millipore). Resulting 
sample was loaded on Superose 6 column (GE Healthcare) equilibrated with Pol II 
buffer, not containing any detergents (see chapter 2.16, Table 10). In such manner 
up to ~1 - 1.5 mg of Pol II-TFIF complex could be obtained from 100 liters of yeast 
culture. Peak fractions were concentrated appropriately for intended use. The 
concentrated protein complex is stable for 2 days at 4 °C. 
 
2.26 Purification of TFIIB 
 
Table 16: Buffers for TFIIB purification 
Buffer Description 
Buffer A  50 mM TRIS-HCl, pH 7.5 (25 °C), 150 mM NaCl, 10 mM -mercaptoethanol, 1x 
protease inhibitors 
Buffer B 50 mM Tris-HCl pH 7.5 (25 °C), 5 mM DTT 
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Full-length TFIIB with a C-terminal His-tag was expressed for 15 h at 20 °C in E. coli 
BL21 (DE3) RIL (plasmid kindly provided by K. Armache). Cells were harvested by 
centrifugation and resuspended in buffer A (Table 16). Cells were lyzed by 
sonication. After centrifugation, the supernatant was loaded onto a 2 mL Ni-NTA 
column (Qiagen), equilibrated with buffer A. After washing with 10 mL of buffer A 
containing 1 M NaCl, bound protein was eluted with buffer A containing 250 mM 
imidazole. The protein was diluted 1:3 with buffer B (Table 16) and was further 
purified by cation exchange chromatography (MonoS 5/5, GE Healthcare). The 
column was equilibrated with buffer B containing 50 mM NaCl, and the protein was 
eluted with a gradient from 50 mM to 1 M NaCl. After concentration, the sample was 
applied to a Superose 6 HR gel filtration column (GE Healthcare) equilibrated with 
Pol II buffer (see chapter 2.16, Table 10).  
 
2.27 Purification of TBP core 
TBP core with an N-terminal His-tag (amino acids 61-240, Z. S. Juo) was expressed 
for 15 h at 20 °C in E. coli BL21 (DE3) RIL (Stratagene). Cells were harvested by 
centrifugation and resuspended in buffer A (25 mM Tris-HCl, pH 8.0 (25 °C), 500 mM 
NaCl, 50 mM ammonium acetate, 10% glycerol). Cells were lyzed by sonication. 
After centrifugation, the supernatant was loaded onto a 2 mL Ni-NTA column 
(Qiagen), equilibrated with buffer A. After washing with 10 mL of buffer A containing 
1 M NaCl, bound protein was eluted with buffer A containing 250 mM imidazole. The 
protein was purified by heparin sepharose column (GE Healthcare). The column was 
equilibrated with buffer A, and the protein was eluted with a gradient from 500 mM to 
1 M NaCl. After concentration, the sample was applied to a Superose 6 HR gel 
filtration column (GE Healthcare) equilibrated with Pol II buffer (see chapter 2.16, 
Table 10).  
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2.28 Electrophoretic mobility shift assay 
 
Table 17: Oligonucleotide sequences for assembly of the initially transcribing complex 
Oligonucleotide Sequence 
Non-template DNA 
strand 
5’-ACGGGCGCCTATAAAAGGCAGTACTAGTAAACTAGTATTGAAAGTACTT 
GAGCTT-3’ 
Template DNA 
strand 
5’-AAGCTCAAGTACTTACGCCTGGTCATTACTAGTACTGCCTTTTATAGGC 
GCCCGT-3’ 
RNA 5’-AAAGACCAGGC-3’ 
 
Nucleic acids corresponding to promoter region and early transcription bubble were 
analyzed for their capability to bind Pol II-TFIIF complex and general transcription 
factors TBP and TFIIB by electrophoretic mobility shift assay. In 15 µL of Pol II buffer 
(see chapter 2.16, Table 10), 20 pmol of nucleic acids were incubated with 20 pmol 
of TBP, TFIIB and 10 pmol of Pol II-TFIIF complex in various combinations (see 
chapter 3.2.4, Figure 20) for 20 minutes at 20 °C. The samples were loaded on a 6% 
native polyacrylamide gel (Novex DNA Retardation Gels) in 1x TBE buffer (see 
chapter 2.4, Table 8). Electrophoresis was carried out at 4 °C at a voltage of 70-90 V 
for 2 hours. Nucleic acids were stained for 30 minutes with 0.01 % SYBR gold in 1x 
TBE buffer and visualized by Typhoon Variable Mode Imager (GE Healthcare) at 495 
nm.  
 
2.29 Assembly of an initially transcribing complex 
TBP (230 µg) was mixed with DNA/RNA (8 nmol) which lead to the formation of a 
reversible precipitate. After 10 minute incubation at 20 °C , TFIIB (560 µg) was added 
and the incubation was continued. Finally Pol II-TFIIF (750 µg) complex was added 
and altogether was agitated for 20 minutes and centrifuged for 5 minutes at 11000 
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rpm. The sample was loaded on a Superose 6 gel filtration column (GE Healthcare) 
using Pol II buffer (see chapter 2.16, Table 10) and peak fractions were analyzed by 
SDS-PAGE. 
 
2.30 Isolation of RNA from protein preparations 
Protein preparations after gel filtration were treated with 1 µL (~23 U, Fluka) of 
Proteinase K in the presence of 5 mM CaCl2. Incubation was performed for 1 hour at 
4 °C on a steering wheel. In order to extract RNA, phenol/chloroform/isoamyl alcohol 
(125:24:1, pH 4) was added to protein preparation in 1:1 ratio (v:v). Such suspension 
was vortexed, followed by 10 minutes long centrifugation at 13000 rpm (4 °C). The 
upper aqueous phase containing the extracted RNA was transferred into a fresh 
Eppendorf tube. 20 µg of glycogen (Fermentas) per milliliter of nucleic acid solution 
were added as a carrier for better precipitation and visualization of RNA pellets. 2-3 
volumes of cold ethanol with addition of sodium acetate to a final concentration of 0.3 
M, pH 5.2 (25 °C) were added. This suspension was vortexed and stored for half an 
hour at -80 °C (or 10 minutes on dry ice). After 20 minutes of centrifugation at 13000 
rpm (4 °C), the supernatant was decanted. The precipitate was washed with cold 
80% ethanol and centrifuged again for 10 minutes. The supernatant was discarded 
and the pellet was air-dried. Finally the RNA pellets were dissolved in 100 µL of 
water. The integrity and size of RNA was checked on RNA denaturing 
polyacrylamide gel (see chapter 2.8). 
 
2.31 Isolation of RNA from polyacrylamide gel 
RNA bands were cut out from the polyacrylamide gel and immersed into an elution 
buffer (0.5 M Tris-HCl pH 7.0 (25 °C), 0.1% (w/v) SDS, 0.1 mM EDTA, 10 mM 
MgCl2). The samples were agitated overnight and in the morning buffer was 
exchanged and agitation continued for another 6 hours. Subsequently, the RNA 
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contained in the elution buffer was extracted and precipitated as described in chapter 
2.30. 
 
2.32 Identification of RNA 
For the identification of isolated RNA in protein extracts, a modification of RLM-RACE 
(rapid amplification of cDNA ends) technique (GeneRacer Kit, Invitrogen) was used 
(Figure 7). Individual reactions were performed according to the protocols provided 
by producer unless stated here. All the reactions were performed in the presence of 
RNase inhibitors (RNaseOut, 40 U) and only in diethylpyrocarbonate (DEPC) treated 
water. After each enzymatic reaction with RNA, RNA was precipitated essentially as 
described in section 2.30 and pellets were dissolved in 8 µL DEPC treated water. 
The isolated RNA was subjected to RNase-free DNase I (NEB) digestion in order to 
remove contaminating genomic DNA. Precipitated RNA was treated with Poly A 
polymerase (5 U, Invitrogen) in the presence of 40 mM TRIS-HCl (pH 8.0 at 25 °C), 
10 mM MgCl2, 2.5 mM MnCl2, 250 mM NaCl, 1 mM ATP (Fermentas), 50 µg/mL BSA 
(NEB) for 30 minutes. Precipitated poly-A RNA was treated with tobacco acid 
pyrophosphatase in order to remove possible CAP structures which could hinder 5’-
ligation of the RNA-oligo by RNA ligase in the next step. Such RNA with 5’-oligo of 
known sequence and 3’-poly-A tail was subjected to SuperScript III reverse 
transcriptase at 50 °C in the presence of oligo-dT primer (24 nt) for first-strand cDNA 
synthesis. The reaction was inactivated at 70 °C for 15 minutes, cooled and RNase H 
was added to degrade the RNA. Such RACE-ready cDNA with known priming sites 
on each end was used as a template for amplification by PCR. Taq polymerase 
(Fermentas) was used to produce 3’ A-overhang-containing products for cloning into 
pCR4-TOPO vectors. Resulting plasmids were propagated in E.coli competent cells 
(One Shot TOP10) and isolated by QIAprep Spin Miniprep Kit Protocol (Qiagen). 
Finally the identity of RNA was determined by DNA-sequencing of the isolated 
plasmids. 
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Figure 7: Identification of RNA by modified RLM-RACE procedure. RNA was isolated from 
purified Pol II-TFIIF protein sample by phenol-chloroform extraction and ethanol precipitation. Final 
product of the RACE procedure was amplified by PCR and cloned into pCR4-TOPO vectors for 
subsequent sequencing. 
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3.1 Structure and mechanism of Pol II CTD phosphatases 
 
3.1.1 Domain organization and structure determination 
A soluble core variant of the yeast Saccharomyces cerevisiae Fcp1, comprising the 
FCPH and BRCT regions could be expressed (Fcp1c, residues 168-606, Figure 8A). 
The protein was purified by Ni2+-NTA affinity chromatography, followed by an anion-
exchange column (MonoQ) (Figure 8B) and a final gel filtration step (Superose12) 
(Figure 8B). The purified protein crystallized (Figure 8C); however, Fcp1c crystals 
were not suited for structural studies. Limited proteolysis of Fcp1c suggested that the 
FCPH and BRCT regions form structured domains connected by a partially exposed 
linker (Figure 8A). Since the catalytic FCPH domain was generally protected from 
proteolytic cleavage, Fcp1 variants comprising only the FCPH domain for 
crystallization were prepared, but these were not soluble under the conditions tested. 
Scp1, which corresponds to the FCPH domain with an N-terminal extension, seemed 
better suited for crystallization (Figure 8A). When the full-length protein was 
expressed in E. coli, the 63 N-terminal residues of the extension were cleaved during 
expression (Fig. 8A), and consequently several Scp1 variants with N-terminal 
truncations were prepared. A variant lacking 76 N-terminal residues (Scp1∆N) was 
highly soluble. The protein was purified using a single gel filtration step after Ni2+-NTA 
affinity chromatography (Fig. 9A) and crystallized in a plate-like morphology (Figure 
9B). Although these crystals were only about 5 µm thick, they diffracted synchrotron 
radiation to better than 2 Å resolution. The X-ray structure was determined by 
multiwavelength anomalous diffraction with the selenomethionine-substituted double 
methionine mutant L165M/L205M of Scp1∆N (Table 18). The structure was refined at 
2.3 Å resolution (Table 18). The refined structure has very good stereochemistry, and 
reveals chemical details. 
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Figure 8: Purification and crystallization of Fcp1. 
(A) Domain organization of Saccharomyces cerevisiae Fcp1 (Sc Fcp1), and human Scp1 (Hs Scp1). 
FCPH and BRCT denote the Fcp1 homology regions and the breast cancer protein related carboxy-
terminal domains, respectively. The amino acids C-terminal of protease cleavage sites are depicted 
with arrows. Protein variants used in this study are indicated below the diagrams. 
(B) Purification of Fcp1c by anion exchange chromatography (MonoQ) and gel filtration (Superose 12). 
Peak fractions are shown on accompanying SDS-gels.  
(C) Crystallization of Fcp1c. Crystals were obtained in 20% PEG4000, 0.5 M Li2SO4, 0.1 M MES pH 
6.0 (left); 1.6 M MgS04, 0.1 M NaMES pH 6.5 (S. Heilmeier, middle); and 22% PEG4000, 0.7 M Li2SO4, 
0.1 M Hepes pH 7.5 (right). 
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Figure 9: Structure of the CTD phosphatase Scp1. 
(A) Purification of Scp1∆N by gel filtration (Superose 12). Peak fraction is shown on accompanying 
SDS-gel. 
(B) Crystallization of Scp1∆N. Crystals were obtained in 20-30% PEG 3300 or PEG 6000 or PEG 
8000, 200 mM NH4OAc, 100 mM citrate buffer pH 5.6, 5 mM DTT. The thin plate-like crystals grew to a 
maximum size of 400x150x5 µm. 
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Figure 9 (continuation) 
 (C) Alignment of human Scp1 (Hs Scp1) with the catalytic FCPH domains of Fcp1 from human (Hs), 
Schizosaccharomyces pombe (Sp), and Saccharomyces cerevisiae (Sc). α-helices and β-strands are  
indicated as cylinders and arrows, respectively. Active site residues are marked with an asterisk below 
the alignment. Residues involved in metal ion and citrate binding are marked below the alignment with 
a pink dot and with a “c,” respectively. Conserved residues are highlighted with the degree of 
conservation decreasing from dark green to yellow. 
(D) Ribbon model of Scp1. Secondary structure elements are colored according to (B). The catalytic 
metal ion is shown as a pink sphere.  
(E) Surface conservation and putative specificity pocket. The molecular surface of Scp1 is colored 
according to amino acid residue conservation as in (B). A citrate ion that binds to the largely conserved 
putative specificity pocket is shown as a stick model. 
 
Table 18: Structure determination and refinement 
Crystal Mutant (L165M/L205M) SeMet MAD Wild type + BeF3- 
Data collection     
Space group P21212   P21212 
Unit cell 
dimensions (Å) 
117.6 x 47.2 x 40.0   117.8 x 47.2 x 40.1 
Wavelength (Å) 0.9795 peak 0.9797 inflection 0.9686 remote 0.9919 
Resolution (Å) 20-2.3 (2.38-2.3) 20-2.3 (2.38-2.3) 20-2.3 (2.38-2.3) 20-2.1 (2.2-2.1) 
Completeness (%) 88.7 (78.7) 90.8 (81.9) 90.9 (80.1) 97.7 (87.5) 
Unique reflections 9,386 (815) 9,639 (857) 9,635 (840) 13,356 (1,520) 
Redundancy 17.4 17.2 17.0 3.8 
Rsym (%) 6.3 (9.8) 5.2 (10.2) 5.2 (8.5) 5.7 (6.2) 
Mean I/ I 21.8 (15.5) 21.1 (12.7) 22.7 (14.0) 19.0 (16.8) 
f´ -7.0 -10.0 -2.3  
f´´ 5.1 2.5 3.5  
Refinement      
Residues   181 (M76-Q255) 181 (M76-Q255) 
Water molecules   131 148 
Magnesium ion   1 1 
Citrate ion   1 1 
RMSD bonds (Å)   0.006 0.006 
RMSD angles (°)   1.29 1.25 
Rcryst (%)   18.7 20.7 
Rfree (%)   23.4 22.7 
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3.1.2 Overall structure 
Scp1 forms a central 5-stranded parallel β-sheet with the strand order 3-2-1-4-5, 
flanked by two α-helices on one side and a two-stranded β-sheet and a short 310-helix 
on the other side (Figure 9D). The signature motif is located at the end of strand β1, 
and together with other conserved residues lines a central depression that forms the 
active site of the enzyme. Although there is no sequence similarity outside the 
signature motif, a DALI search (Holm and Sander, 1995) revealed that the core fold of 
Scp1 largely corresponds to that of phosphoserine phosphatase (PSP, Wang et al., 
2001) and β-phosphoglucomutase (β-PGM, Lahiri et al., 2003), both members of the 
DXDX(T/V) superfamily of phosphohydrolases and -transferases, and to 1, 2-L-
haloacid dehalogenase (Ridder et al., 1999) (Figure 10). The major structural 
difference between these enzymes lies in a large insertion after strand β1, which may 
determine substrate specificity (“insertion domain,” Figures 9, 10). Within the core 
domain, Scp1 lacks a sixth β-strand that is present in the central β-sheet of the other 
enzymes (Figure 10). 
Homology modeling of the FCPH domain of human Fcp1 showed that residues 
forming the hydrophobic core are conserved, although the overall sequence identity in 
the FCPH domains of human Scp1 and Fcp1 is only 21% (Figure 9C). This indicates 
that this structure is a valid model for the Fcp1 FCPH domain, and that mutational 
data on Fcp1 can be interpreted based on the Scp1 structure.  
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Figure 10: Comparison of DXDX(T/V) superfamily enzyme structures.  
(A-D) Ribbon models of the DXDX(T/V) superfamily phosphotransferases Scp1 (A) (this study), 
phosphoserine phosphatase PSP (B) (PDB code 1F5S, Wang et al., 2001), β-phosphoglucomutase β-
PGM (C) (PDB code 1O03, Lahiri et al., 2003), and 1, 2-haloacid dehalogenase HAD (D) (PDB code 
1QQ5, Ridder et al., 1999). Structural similarities were found with the DALI server (Holm and Sander, 
1995), which detects fold similarities by superposing a query structure onto representative structures in 
the database and calculating the RMS deviation of carbon-α atom positions. The catalytic core domain 
of the DXDX(T/V) enzymes, which includes a central parallel β-sheet and its flanking regions, is shown 
in brown. The insertion domain of Scp1 and the corresponding regions in the other enzymes are shown 
in turquoise. The catalytic metal ion is depicted as a pink sphere. 
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3.1.3 Phosphatase activity 
To investigate whether the structural resemblance of Fcp1 and Scp1 is reflected in 
comparable enzymatic properties, a highly purified recombinant human Scp1∆N and 
yeast Fcp1c were subjected to a spectrophotometric assay based on cleavage of the 
nonspecific substrate para-nitrophenylphosphate (pNPP), and the catalytic 
parameters were determined (see chapter 2.14). Both proteins readily cleaved pNPP 
in a pH-dependent manner, with maximum activity at pH 5.5. Michaelis-Menten 
kinetic analysis revealed KM values of 6 mM and 32 mM for human Scp1∆N and yeast 
Fcp1c, respectively (Figure 11A). These KM values are comparable to published 
values for endogenous S. cerevisiae Fcp1 (60 mM, Kobor et al., 1999) and full-length 
recombinant Schizosaccharomyces pombe Fcp1 (19 mM, Hausmann and Shuman, 
2002). The turnover numbers kcat were 17 s–1 and 33 s-1 for human Scp1∆N and yeast 
Fcp1c, respectively. Thus the recombinant proteins used in these structural studies 
are active and the structural similarity of the FCPH domains of Scp1 and Fcp1 is 
reflected in similar enzymatic properties, although Fcp1 has slightly higher catalytic 
activity. 
 
3.1.4 Specific inhibition 
To investigate the catalytic mechanism, the effect of various inhibitors of phosphoryl-
transfer reactions on the activity of Scp1∆N and Fcp1c were tested (Figure 11B). 
Phosphatase activity of both enzymes was essentially abolished by the beryllofluoride 
anion BeF3-, produced in situ from BeCl2 and NaF. In contrast, BeCl2 or NaF alone did 
not have a strong effect on activity. The inhibitory effect of AlF4- was less severe, and 
sodium vanadate only inhibited activity slightly. Magnesium ions were essential for 
activity. The data indicate the presence of a catalytic aspartate residue, as BeF3- can 
form a stable tetrahedral adduct with catalytic aspartate side chains, mimicking a 
labile phosphoaspartate intermediate (Cho et al., 2001b; Yan et al., 1999), whereas 
AlF4- tends to mimic a phosphate (Chabre, 1990). The response of Fcp1 and Scp1 to 
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the inhibitors was very similar, indicating that these enzymes share a common 
catalytic mechanism. 
 
Figure 11: Catalytic activity and specific inhibition of CTD phosphatases. 
(A) Determination of catalytic parameters. Catalytic activity of Scp1∆N and Fcp1c was determined as 
described in chapter 2.14. To derive KM and kcat, the initial velocities v at seven different substrate 
concentrations were plotted according to Eadie-Hofstee against the velocities divided by the substrate 
concentration. The plot was fitted to the equation v = Vmax - KM(v/[S]). 
(B) Specific inhibition. The inhibitors were added to reaction mixtures (see chapter 2.14) in the 
following concentrations: 1 mM sodium vanadate (Na3VO4), 1 mM sodium fluoride (NaF), 100 µM 
beryllium chloride (BeCl2), 100 µM aluminum chloride (AlCl3), a mixture of 1 mM sodium fluoride and 
100 µM beryllium chloride (to produce the beryllofluoride anion BeF3
- in situ), and a mixture of 1 mM 
sodium fluoride 100 µM aluminum chloride (to produce AlF4
- in situ). 
 
3.1.5 Active center 
The enzymatic and inhibitory data are reflected in the active site structure. Mutational 
analysis of Fcp1 from S. pombe has defined 11 amino acid residues in the FCPH 
domain that are important for catalytic activity (Hausmann et al., 2004; Hausmann 
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and Shuman, 2003). The Scp1 structure shows that seven out of these residues, 
including three residues in the signature motif, cluster in the central depression and 
form the active site (Table 19, Figure 12). The remaining four residues are not found 
in the active center depression, and are involved in salt bridges or hydrophobic core 
interactions, predicting that their mutation disrupts the domain structure (S. pombe 
Fcp1 residues R223, Y237, Y249, and D258, corresponding to Scp1 residues R132, 
F164, Y158, and D167, respectively, Figure 9C). The seven active site residues 
generally superimpose well with corresponding residues in structures of other 
enzymes of the DXDX(T/V) superfamily (Figure 12C). In the case of K190, the 
counterpart residues in PSP and PGM protrude from different locations of the protein 
backbones, but functional head groups occupy the same position. This is also true for 
the counterpart of D206 in PSP. Consistent with the requirement for metal ions in 
catalysis, the active site comprises a metal ion that is coordinated by residues D96, 
D98, N207, and two water molecules. The metal ion shows the highest peak in a 
difference Fourier map phased with the final model lacking any water molecules or 
ions (9.8σ). 
 
Table 19: Active site residues in DXDX(T/V) phosphotransferases and –hydrolases1 
H.s. Scp1 S.c. Fcp1 S.p. Fcp1 PSP β-PGM Functional or structural role 
D96 D180 D170 D11 D8 Phosphoryl acceptor, metal coordination 
D98 D182 D172 D13 D10 General acid/base, metal coordination 
T100 T184 T174 T15 V12 Positions side chains of D96 and N207 
T152 T270 T243 S99 S114 Transition state stabilization 
K190 K307 K280 K144 K145 Transition state charge stabilization 
D206 D324 D297 D171 E169 Salt bridge with K190 in Scp1 
N207 D325 D298 D167 D170 Metal coordination 
1Scp1, small CTD phosphatase 1; Fcp1, TFIIF-dependent CTD phosphatase 1; PSP, phosphoserine phosphatase 
(PDB codes 1F5S, 1J97); β-PGM, β -phosphoglucomutase (PDB codes 1O08, 1O03). 
2These residues protrude from different sites of the protein backbones but their functional head groups are at 
positions equivalent to those in the Scp1 structure (see Figure 12C). 
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Figure 12: Active site and mimicry of the phosphoaspartate intermediate. 
(A) Electron density. The final 2Fo-Fc density is shown for residues in the active site (black, contoured 
at 1.4σ). For the beryllofluoride anion, which mimics the phosphoasparate-96 intermediate, the Fo-Fc 
density calculated from the model lacking the beryllofluoride is shown (green, contoured at 3.0σ), and 
the 2Fo-Fc density is omitted. 
(B) Active site interactions. Hydrogen bonds are shown as dotted lines, and metal ion-ligand 
interactions as solid black lines. The metal ion is coordinated by the D96 side chain oxygen (2.3 Å), by 
the D98 carbonyl oxygen (2.1 Å), by the N207 side chain oxygen (2.3 Å), by a fluorine atom in the 
beryllofluoride (2.2 Å), and by two water molecules (2.4 Å, 2.5 Å). 
(C) Superposition of active site residues in Scp1 (yellow), phosphoserine phosphatase (light grey, PDB 
code 1F5S, Wang et al., 2001), and β-phosphoglucomutase (dark grey, PDB code 1O08, Lahiri et al., 
2003). Six out of seven active site residues are shown. 
 
3.1.6 Catalytic mechanism 
The structural and functional data strongly suggest that the catalytic mechanism of 
Scp1 and Fcp1 involves the metal-dependent formation of a phosphoaspartate 
intermediate. This mechanism was suggested for S. pombe Fcp1 based on 
biochemical data (Hausmann and Shuman, 2003), and was shown for other 
DXDX(T/V) superfamily enzymes, which use the N-terminal aspartate in the signature 
motif as the phosphoryl acceptor (Cho et al., 2001b; Lahiri et al., 2003). 
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To directly show that the first aspartate in the signature motif acts as the phosphoryl 
acceptor in Scp1, the crystals were soaked with trifluoroberyllate (beryllofluoride). A 
difference Fourier map revealed a beryllofluoride anion bound to one oxygen atom of 
the D96 side chain carboxylate (Figure 12A). The metal ion is bound to the other D96 
side chain oxygen atom, and shows an approximate octahedral coordination with 
metal-ligand distances of 2.0-2.3 Å (Figure 12B). A metal ion is found at an equivalent 
position in structures of PSP (Wang et al., 2001) and β-PGM (Lahiri et al., 2003). 
Thus beryllofluoride mimics the labile phosphoaspartate intermediate formed at 
residue D96 in the active center of Scp1. Consistently, mutation of this aspartate in 
Scp1∆N (Figure 13A) or Fcp1c (not shown) to alanine or aparagine abolished activity. 
The same mutation abolishes activity of full-length S. cerevisiae Fcp1 (Kobor et al., 
1999) and S. pombe Fcp1 (Hausmann and Shuman, 2002). These data establish D96 
as the phosphoryl acceptor in Scp1 (Figure 13B). The conservative Scp1 mutation 
D96E retains some activity (Yeo et al., 2003), apparently because the carboxylate 
group can still act as the phosphoryl acceptor. 
The functional role of the other active site residues can be inferred from their relative 
location and from comparison with other enzymes of the DXDX(T/V) superfamily. In 
addition to metal ion binding, D98 may act as a general acid/base, donating a proton 
to the leaving group (the CTD serine side chain). D98 may also position and activate 
a water molecule for the second step, dephosphorylation of the phosphoasparate and 
regeneration of the free D96 side chain. The metal ion and the head groups of the 
side chains of T152 and K190 all lie in a plane slightly above the position of the 
beryllium atom, and thus within a presumed equatorial plane of a pentavalent trigonal 
bipyramidal transition state. The metal ion and residues T152 and K190 are therefore 
expected to stabilize the geometry of the transition state and to partially neutralize its 
charge. Mutational analysis supports the proposed roles of the individual residues 
that form the active center (Figure 13A). While alanine replacements of T152 and 
K190 completely abolish enzymatic activity, T152S and N207D retain some activity 
due to the similar chemical properties.  
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Figure 13: Mechanism of CTD phospatases of the Fcp1 family.  
(A) Mutational analysis of the active site mutants. Each mutant was tested for ability to cleave 
nonspecific substrate pNPP as described in chapter 2.15. 
(B) Proposed mechanism of CTD phosphatases Scp1/Fcp1. The reaction mechanism involve the 
formation of a phosphoaspartyl intermediate, followed by recycling of the catalytic side chain with the 
use of a nucleophilic water molecule. Mechanism was drawn with MDL ISIS/Draw.  
 
3.1.7 CTD specificity 
Specificity for the CTD may result from recognition of CTD residues neighboring the 
phosphorylated target side chain. There is evidence that CTD recognition involves the 
specific insertion domain of Scp1 and Fcp1, which directly follows the signature motif 
(Figures 9C, 10A). The insertion domain and the core fold line a deep pocket, which 
binds a citrate ion that was present in the crystallization solution (Figure 9E). The 
citrate is only 8 Å away from the beryllofluoride. The pocket is largely hydrophobic, 
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with many of the lining residues conserved between Scp1 and Fcp1, including several 
residues that contact the citrate (Figure 9C). The insertion domain of Scp1 forms a 3-
stranded β-sheet, and sequence conservation indicates that it must be similar in 
Fcp1, except for the two loops of the sheet that are longer in yeast Fcp1 (Figure 9C). 
The insertion domain of PSP, β-PGM and HAD is involved in substrate binding, but 
has a totally different structure (Figure 10), as expected for different substrate 
specificities. Together these findings suggest that the Fcp1/Scp1 pocket between the 
insertion domain and the active site binds the CTD and confers substrate specificity. 
Mutational analysis of the presumed substrate pocket could confirm this proposal. 
Consistent with CTD binding to the specificity pocket, S. pombe Fcp1 activity requires 
at least four N-terminal and two C-terminal CTD residues flanking phosphoserine 2, 
and single alanine mutations of the flanking Tyr1 and Pro3 decrease activity sixfold 
(Hausmann et al., 2004). However, Fcp1 and Scp1 can dephosphorylate both Ser5 
and Ser2, with some preference for either of these serines (Hausmann and Shuman, 
2002; Lin et al., 2002a; Yeo et al., 2003). Since both serines are flanked on the C-
terminal side by a proline, it is likely that the CTD phosphatases bind the adjacent 
prolines Pro3 or Pro6, and preferential dephosphorylation of Ser2 and Ser5 is 
achieved by binding to other nearby residues. Indeed, the Pro3 side chain binds to a 
hydrophobic pocket in the known CTD peptide complex structures (Fabrega et al., 
2003; Verdecia et al., 2000; Meinhart and Cramer, 2004) and specific recognition of a 
flanking proline is consistent with Fcp1 inhibition by the prolyl isomerase Pin1 (Xu et 
al., 2003). A better understanding of CTD specificity however requires structure 
determination of Fcp1 or Scp1 in complex with a phosphorylated CTD peptide.  
 
3.1.8 The Pol II subcomplex Rpb4/7 recruits Fcp1 
Specificity of Fcp1 for the CTD may not only result from direct recognition of the CTD 
residues but also from binding of Fcp1 to a docking site on Pol II distinct from the 
CTD (Chambers et al., 1995). To investigate if the docking site is on the ten-subunit 
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core of Pol II or on the heterodimeric polymerase subcomplex Rpb4/7, reconstitution 
of Fcp1 with Pol II core complexes and complete Pol II (Pol II core plus recombinant 
Rpb4/7, Armache et al., 2003) was tried. To this end pure endogenous yeast Pol II 
core with an excess of recombinant Fcp1c was incubated, either in the presence or 
the absence of an additional excess of recombinant Rpb4/7 complex, and the 
samples were subjected to size exclusion chromatography. In both cases, two 
separated peaks were obtained. In the absence of Rpb4/7, the first peak 
corresponded to the Pol II core alone, and the second peak contained Fcp1c. In the 
presence of Rpb4/7, however, the first peak contained all 12 subunits of Pol II and 
Fcp1c, representing a reconstituted Pol II-Fcp1c complex (Figure 14). Since formation 
of a Pol II-Fcp1c complex relied on the presence of Rpb4/7, Fcp1 interacts with Pol II 
mainly via the Rpb4/7 subcomplex.  
 
Figure 14: Reconstitution of the Pol II-Fcp1 complex 
Purified endogenous yeast Pol II core enzyme was incubated with an excess of recombinant Rpb4/7 
subcomplex and Fcp1c and the resulting mixture was separated on a Superose 6 gel filtration column. 
The elution profile was normalized by the distribution coefficient (Ve = elution volume, V0 = void 
volume, Vi = inner volume as determined by retention of acetone). The two peak fractions were 
analyzed by SDS-PAGE. The first peak corresponds to a reconstituted Pol II-Fcp1 complex.  
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Consistent with these results, S. pombe Fcp1 contacts Rpb4 in a Pol II-TFIIF-Fcp1 
complex and binds to Rpb4/7 in vitro (Kimura et al., 2002). The direct interaction of 
Fcp1 with Pol II via the Rpb4/7 complex may result in functional differences between 
Fcp1 and Scp1, but further studies are required to analyze these. Rpb4/7 is located 
directly adjacent to the last ordered residues of the largest Pol II subunit, which form 
the beginning of a linker to the disordered CTD, and may therefore recruit Fcp1 to the 
phosphorylated CTD (Figure 15, Armache et al., 2003; Bushnell and Kornberg, 2003). 
Stable association of Fcp1 with Pol II in vivo may however require additional 
interactions (Figure 15). In particular, Fcp1 binds the phosphorylated CTD (Yu et al., 
2003), and the polymerase-associated general transcription factor TFIIF, which also 
stimulates Fcp1 activity (Chambers et al., 1995). The C-terminal end of Fcp1 includes 
a short helix that interacts with the large subunit of TFIIF (Archambault et al., 1998; 
Kamada et al., 2003; Nguyen et al., 2003b).  
 
Figure 15: Protein-protein interaction network in a Pol II-TFIIF-Fcp1 complex. 
The Pol II core enzyme and the Rpb4/7 subcomplex are in black and pink, respectively (Armache et 
al., 2003). Fcp1 is in blue, with the FCPH domain modeled with the Scp1 structure lacking the two C-
terminal helices, and the BRCT domain modeled as a canonical BRCT domain (PDB code 1JNX, 
Williams et al., 2001). The C-terminal Fcp1 helix is shown in complex with the TFIIF large subunit 
winged helix domain (red, PDB code 1J2X, Kamada et al., 2003). Protein-protein interactions are 
indicated by arrows. 
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Recently an additional interaction between Fcp1 and Pol II was reported, distinct from 
both the CTD and Rpb4/7 subcomplex (Suh et al., 2005). The authors speculated that 
this interaction might mediate the stimulatory effect of Fcp1 on transcription 
elongation. These multiple interactions may play a role in regulating Fcp1 activity 
during the transcription cycle, and may also allow for dephosphorylation of the 
repetitive CTD in a pseudo-processive manner, although isolated Fcp1 is a 
distributive enzyme, apparently associating with the CTD and dissociating from it for 
each catalytic cycle (Hausmann et al., 2004). 
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3.2 Preparation of the Pol II-TFIIF complex 
 
3.2.1 Expression of TFIIF in E. coli 
Initiation complex assembly requires several general transcription factors, among 
them multisubunit factors (TFIIF and –H), which for a long time have not been 
available in large quantities by overexpression but had to be obtained in lengthy 
multi-step purification procedures with very low yields. Whereas yeast TBP and the 
small general factors TFIIB and TFIIA can be produced in large quantities and pure 
form by overexpression in bacteria (Chasman et al., 1993; Geiger et al., 1996), large-
scale preparation of the yeast general transcription factors TFIIF and –H is 
challenging since these are multiprotein complexes. Expression of single subunits of 
these complexes in most cases leads to insoluble samples.  
Bacterially expressed human RAP30 and RAP74 can associate in vitro, but very 
inefficiently even after denaturation of the two proteins with urea and subsequent 
renaturation (Burton et al., 1988; Wang et al., 1993). This observation is explained by 
the structure of the RAP74/RAP30 dimerization domain (see chapter 1.4, Figure 4A). 
Since β-strands from both the RAP30 and RAP74 subunits contribute to the three 
intertwined β-barrels (Gaiser et al.,2000), it seems that formation of the triple barrel 
requires co-folding of subunits, as opposed to docking of stable monomers (Wei et 
al., 2001). Co-expression of human RAP30 and RAP74 (Tan et al., 1994) as well as 
S. pombe TFIIF in insect cells (Spahr et al., 2003) yielded an assembled form of 
active TFIIF. Co-expression of human RAP30/74 in bacteria was also possible (Tan 
et al., 1995). 
Biochemical analysis of yeast TFIIF has been hampered by the inability to produce 
recombinant yeast TFIIF due to the reported toxicity of the Tfg1 subunit in E. coli 
(Henry et al., 1994). Only one successful trial to express yeast Tfg1-Tfg2 complex 
that decreased toxicity/instability of the expression plasmid was reported. It included 
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the use of a low copy broad host range vector for cloning of Tfg1 and Tfg2 under the 
control of the adjacent T7 promoters, a specific combination of different tags, as well 
as the induction of expression by infection with bacteriophage λ in a recombinant E. 
coli strain lacking T7 RNA polymerase (Ziegler et al., 2003).  
Figure 16: Domain organization of TFIIF and E. coli expression trials.  
(A) Domain organization of yeast TFIIF.  
(B) Variants of TFIIF expressed in E. coli. Truncated variants of Tfg1 and Tfg2 could be coexpressed 
using a bicistronic vector, as shown on the SDS gel after Ni-NTA affinity purification (left). Truncated 
Tfg1 (234-735) and Tfg2 (46-144::192-273) could be additionally coexpressed from bicistronic vector 
by co-transformation with full-length Tfg3. SDS gel after a Superose 6 gel filtration column is shown 
(right). “::” indicates deletion. 
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Two possible routes for obtaining large quantities of the yeast TFIIF in free form and 
bound to Pol II were explored during this work. Together with the research technician 
in our laboratory, Claudia Buchen, expression of the yeast 3-subunit TFIIF in E. coli 
was tried. Many recombinant variants were produced (chapter 2.19, Table 12), and 
different expression strategies were tried. Those included co-transformation of 
plasmids carrying individual subunits, bicistronic expression, and expression of Tfg1 
and Tfg2 subunits under the control of adjacent T7 promoters on a single vector and 
co-transforming with Tfg3 in pET expression system. While TFIIF comprised of 
truncated subunits could be expressed (Figure 16), a 3-subunit, full-length initiation 
competent TFIIF could not be expressed in E. coli.   
Moreover, a reconstitution of the TFIIF complex was tried by mixing the singly 
expressed subunits in variety of combinations. None of these trials, however, 
resulted in a complete and stoichiometric three-subunit complex, capable of binding 
Pol II. This leads to the conclusion, that it is not possible to produce a complete yeast 
TFIIF in E. coli under the conditions tested. Variants of Tfg2 were expressed alone in 
E. coli, but did not bind the 12-subunit Pol II. The overview of different trials of 
bacterial expression of TFIIF is given in the chapter 2.19, Table 12. 
 
3.2.2 Isolation of TFIIF from yeast 
Consequently we switched to the yeast system with the help of Dr. Katja Sträßer 
(Gene Center) who produced a strain, with introduced tandem affinity purification 
(TAP)-tag on either Tfg1 or Tfg2. TAP is based on two successive affinity 
chromatography steps (Rigaut et al., 1999; Puig, et al., 2001). The tag fused to a 
target protein is composed of protein A having very high affinity for IgG, a TEV 
protease cleavage site, and the calmodulin-binding peptide having high affinity for 
calmodulin. TAP purification enables isolation of native protein complexes as well as 
co-purifications and identification of in vivo interacting proteins. 
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For TAP purification, yeast extract containing the TAP-tagged TFIIF was mixed with 
the IgG affinity resin. Bound TFIIF was released by TEV protease. This eluate was 
further used for gel filtration. Soluble stoichiometric TFIIF complex was obtained. Due 
to the high affinity of TFIIF for Pol II, a significant portion of Pol II stayed bound to 
TFIIF even after more stringent salt washes. However, after extensive purification 
optimization and up-scaling trials, the amount of the soluble material obtained was 
not sufficient for structural studies. Major obstacles were high losses during gel 
filtration and during the concentration step. These trials established, however, the 
importance of a non-ionic detergent for successful isolation of the complex from 
yeast extract, its solubility and enrichment.  
The initial trials included Nonidet P-40 (Igepal CA-630), a non-ionic detergent which 
has a high absorption at 280 nm making a high background, and therefore it is 
unsuitable for chromatographic purification. Further, this impaired concentration 
measurements with standard protein concentration measurement assays. In addition, 
it is a very heterogeneous compound highly inappropriate for structural studies that 
require crystallization. The new detergent of choice was dodecyl-β-D-maltoside. In 
buffer containing this detergent, the protein eluted with a Gaussian-shaped peak. 
Dodecyl-β-D-maltoside is often used in structural studies of membrane-associated 
proteins and does not absorb at the wavelengths which are routinely used for protein 
concentration determination. 
  
3.2.3 Overexpression of TFIIF in yeast 
In order to produce larger amounts of TFIIF, a new strategy was introduced. Genes 
for each of the three subunits were subcloned in the separate YIplac yeast-E. coli 
shuttle vectors carrying different in vitro mutagenized yeast genes (LEU2, TRP1 and 
URA3, respectively) (Gietz and Sugino, 1988). Each subunit was placed under the 
control of the relatively strong alcohol dehydrogenase 1 (ADH1) promoter followed by 
a corresponding terminator (figure 17). To the middle subunit, Tfg2, a TAP tag was 
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added to the C-terminal end. Such plasmids were linearized and subsequently used 
for yeast transformation. Due to the homologous recombination, such linearized 
plasmids containing ADH1 promoter and individual TFIIF subunits integrate into the 
yeast chromosomes.  
Figure 17: Generation of yeast TFIIF overexpression strain. Each of the TFIIF subunits was 
cloned into E. coli-yeast shuttle vector under the control of strong ADH1 promoter as described in 
chapter 2.20. The plasmids were consequently linearized and used for yeast transformation (DSY5 
strain). Due to the homologous recombination, plasmids were integrated into yeast genome. 
 
In order to test the newly created strain for overexpression and compare it with the 
TFIIF yield resulting from expression under the control of the endogenous promoter, 
the protein complex from both strains was purified in an analogous manner. Relative 
comparison of the TFIIF yield by dot blot analysis (Borggrefe et al., 2001) revealed 
substantially higher expression of TFIIF in the yeast strain where the protein 
expression was under the control of the ADH1 promoter (Figure 18A, B). However, 
although the yield of TFIIF was raised, the amounts gained even from 16 liters of 
yeast culture, after all the purification and concentration steps, still did not exceed 
several micrograms and did not suffice for structural studies of the complex.  
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Figure 18. Overexpression of TFIIF in yeast  
(A) Comparison of TFIIF-TAP yield, expressed under control of ADH1 and endogenous promoter. 
Protein fractions were analyzed by dot blots (chapter 2.24). In order to enable relative comparison, 
proteins were purified identically from the same amount of yeast culture (2L of yeast culture harvested 
at OD600~3).  
(B) Small-scale TFIIF purification from overexpression strain. In this case 2L of yeast culture of 
OD600~3 was used. After TEV cleavage, protein sample was loaded directly onto a gel filtration column 
(Superose 6).  
(C) Large-scale TFIIF purification from overexpression strain. First gel filtration step in the presence of 
detergent (dodecyl-β-D-maltoside) corresponding to 100 L of yeast culture (OD600~3) is shown. Elution 
profile was analyzed by SDS-PAGE. Fractions 3-5 contain stoichiometric Pol II-TFIIF complex. 
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In order to up-scale significantly, a substantial amount of the input yeast culture had 
to be used. Initially as much as 200 liters of yeast culture resulted only in 70 µg of 
crystallography-grade 15-subunit ~0.7 kDa stoichiometric Pol II-TFIIF complex 
(Figure 18C, corresponding to 100 liters). It seems that the binding of TFIIF on the 
Pol II surface prevents the dissociation of Rpb4/7 subcomplex as previously reported 
(Edwards et al., 1990). This implies binding of TFIIF over Rpb4/7 surface which 
agrees with the low resolution architecture of Pol II-TFIIF complex by electron 
microscopy. By increasing the amount of IgG resin (30 mL per 1.1 kg of cell pellet), 
more Pol II-TFIIF complex could be isolated which allowed omitting the detergent in 
the final gel filtration step. The input yeast culture could be reduced down to 100 
liters per a single purification and the yield was increased dramatically, reaching 1 to 
1.5 mg of pure material, suitable for crystallographic studies and assembly of the PIC 
and early transcribing complexes (Figure 19, 200 micrograms loaded on the column). 
Figure 19: Optimized Pol II-TFIIF complex purification. Second gel filtration step without presence 
of detergents is shown. In this case 200 µg of Pol II-TFIIF complex after first gel filtration was loaded 
on the column. Peak fractions were analyzed by SDS-PAGE. 
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Crystallization trials of Pol II-TFIIF complex were performed and yielded crystals in 
the conditions characteristic for the growth of the Pol II crystals. Synchrotron 
diffraction data were collected to 4.2 Å resolution. After molecular replacement with 
the refined model of 12-subunit Pol II (Armache et al., 2005), electron density maps 
did not reveal any additional density that could be attributed to TFIIF. Additionally, 
the crystals were washed, dissolved in SDS-loading dye and loaded on an SDS-gel. 
The individual bands were cut out, analyzed by MALDI peptide mass fingerprints and 
did not reveal any TFIIF subunits. Thus the Pol II-TFIIF complex had apparently 
dissociated during crystallization, and the free Pol II was crystallized. Possibly, TFIIF 
binds Pol II only by a few distinct globular domains connected through extensive 
linkers essential for biological function, and is only sufficiently stabilized by other 
general transcription factors of the transcription machinery.  
 
3.2.4 Assembly of an initially transcribing complex (ITC) 
With the Pol II-TFIIF complex being available for the first time in sufficient amounts, 
new routes towards structural studies of the preinitiation and early transcribing 
complexes are open. In cooperation with A. Jawhari from the laboratory, it was 
shown that the Pol II-TFIIF complex preparations can be used to assemble an ITC. 
An electrophoretic mobility shift assay was used to monitor the step-wise assembly of 
recombinantly expressed general transcription factors TBP and TFIIB and Pol II-
TFIIF complex on the DNA promoter region in the presence of 11-nucleotide long 
RNA, mimicking an initially transcribed pre-mRNA (figure 20C). Both TFIIB and TBP 
separately bound promoter DNA, (Figure 20C, lanes 2 and 3). When mixed together, 
a TBP-TFIIB-DNA/RNA complex was formed (Figure 20C, lane 5). As expected, Pol 
II-TFIIF complex alone (Figure 20C, lane 4) as well as with TFIIB-TBP complex (lane 
6) shifted dramatically the promoter DNA band. These two complexes, however, 
cannot be distinguished due to their size and consequently their poor resolution on 
the native gel used. 
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Figure 20: Assembly of the initially transcribing complex.  
(A) Reconstitution of ITC complex. ITC was assembled in vitro as described in chapter 2.29 and 
separated on a Superose 6 gel filtration column.  
(B) The two peak fractions were analyzed by SDS-PAGE. The first peak corresponds to a 
reconstituted ITC.  
(C) Stepwise assembly of ITC monitored by electrophoretic mobility shift assay (EMSA). Lane 6 
represents reconstituted ITC. 
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Additionally, ITC was analogously assembled in vitro and applied to a gel filtration 
column (Figure 20A). The first peak fraction contained all 17 polypeptides used for 
the assembly representing the yeast initially transcribing complex assembled in vitro 
that can be used for structural studies (Figure 20A, B). Preliminary crystallization 
trials resulted in small crystals, but their contents remain to be determined (A. 
Jawhari, personal communication).  
To conclude, the large-scale preparation of the Pol II-TFIIF complex is a milestone 
towards structural studies of the yeast PIC and early transcribing complexes that will 
ensure new insight into the mechanism of eukaryotic gene expression. 
 
3.2.5 Presence of 5.8S rRNA in Pol II-TFIIF preparations 
The gel filtration profile of the Pol II-TFIIF complex showed that the absorption at 260 
nm is higher than the absorption at 280 nm (Figures 18C, 19) which is indicative of 
nucleic acid binding. Such relation was kept even during fractional ammonium sulfate 
precipitation which includes a very high salt concentration. Selective digestion of the 
protein preparation with both RNase and DNase (RNase-free) independently, helped 
to identify the nucleic acid. While DNase I (RNase-free) digestion did not significantly 
influence the gel filtration profile, the RNase I digestion resulted in significantly 
reduced absorption at 260 nm at the retention volume of the Pol II-TFIIF complex 
(data not shown). This implies the presence of an RNA species bound to the 
complex. Upon phenol/chloroform extraction and ethanol precipitation, the nucleic 
acid sample was loaded on an 8% urea denaturing polyacrylamide gel. The gel 
showed a prominent band of ~160 nucleotides, resistant to DNase I cleavage, 
confirming it to be RNA. In order to establish the RNA identity, a modification of the 
RACE method (chapter 2.32, Figure 7) was employed to synthesize cDNA which was 
then further amplified by PCR and cloned into pCR4-TOPO vector for sequencing. 
Sequencing of the vector surprisingly identified 5.8S rRNA to be present in the Pol II-
TFIIF complex preparation. 5.8S rRNA is a component of the large ribosomal 
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subunit, which is synthesized together with 18S and 25S rRNA as a single 
polycistronic rRNA precursor by RNA Pol I (Kressler et al., 1999; Venema and 
Tollervey, 1999; Fatica and Tollervey, 2002). In order to investigate the potential 
specificity of the interaction between Pol II-TFIIF complex and 5.8S rRNA, our 
collaborators (S. Ferreira-Cerca and H. Tschochner) immunoprecipitated the Pol II-
TFIIF complex and searched for different RNA species by Northern blotting. However 
they did not observe any significant association of 5.8S rRNA when compared to the 
background under conditions tested. Hence, the observed interaction of 5.8S rRNA 
with the Pol II-TFIIF complex is apparently nonspecific and could result from the 
nucleic acid binding affinity of the Pol II-TFIIF complex and huge abundance of 5.8S 
rRNA in the cells. Additionally, interactions of 5.8S rRNA with 28S rRNA and 
ribosomal protein are sufficiently weak to permit a reversible dissociation of the 5.8S 
rRNA molecule even under relatively mild conditions (Nazar, 1978; Lo et al., 1987). 
Finally, many ribosomal proteins are often co-purified during the immunoaffinity 
purification using TAP-tags. 
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Conclusions 
In this thesis the high-resolution crystal structure of human Scp1 was reported. The 
structure of the CTD phosphatase Scp1 reveals a core fold similar to that of other 
enzymes of the DXDX(T/V) superfamily that are essentially unrelated in sequence, 
and is a good model for the catalytic FCPH domain of all Fcp1 and Scp1 enzymes. 
Biochemical and further structural studies of recombinant Scp1 and Fcp1 revealed 
the catalytic mechanism of these enzymes. The signature motif is part of a central 
depression that forms the active site and binds a metal ion. Catalysis involves the 
metal-assisted phosphorylation of the first aspartate in the DXDX(T/V) signature 
motif. Magnesium ions are essential for Fcp1 and Scp1 activity, and the 
trifluoroberyllate anion inhibits activity by forming a stable tetrahedral adduct with the 
catalytic aspartate side chain, mimicking a labile phosphoaspartyl intermediate. A 
conserved hydrophobic pocket formed between the active site and the Fcp1/Scp1-
specific insertion domain is likely involved in CTD recognition. Specificity of Fcp1 for 
the Pol II CTD may additionally arise from multiple interactions with the Pol II 
machinery, including docking of Fcp1 to the Rpb4/7 subcomplex, which is located 
adjacent to a protein linker connecting to the CTD. Whereas the catalytic mechanism 
of Fcp1/Scp1 phosphatases is now well understood, the basis for their CTD 
specificity remains to be fully established. Open questions on CTD phosphatases 
and Pol II recycling include details of the interactions between the phosphatase, Pol 
II, and the CTD, and the timing of these transient protein-protein interactions during 
the transcription cycle. In addition, the question on communication between the CTD 
phosphatases, kinases and other CTD-interacting proteins has yet to be answered. 
Whereas yeast TBP and other small general transcription factors can be produced in 
large amounts in bacteria, TFIIF was the last obstacle towards structural studies of 
the minimal preinitiation complex and early transcribing complexes. This thesis 
describes different attempts to overexpress and purify TFIIF from bacteria. None, 
however, resulted in a full-length 3-subunit stoichiometric complex. Pol II-TFIIF 
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complex from yeast could be isolated using a TAP purification in scarce amounts, not 
amenable for crystallographic studies. Consequently, an overexpression system in 
yeast has been developed by placing individual TFIIF subunits under the control of 
the ADH1 promoter. Using up to 200 liters of yeast culture it was possible to establish 
a purification protocol that allowed for isolation of milligram quantities of pure 
stoichiometric Pol II-TFIIF complex. This complex was further shown to assemble, 
together with the DNA containing promoter and initial coding region, a short RNA 
stretch mimicking a transcribed pre-mRNA, TBP and TFIIB, into ITC. Only pieces of 
this puzzle have so far been visualized either by crystallography or NMR, or at very 
low resolution by electron microscopy. The exact interplay of those subcomplexes 
and concomitant conformational changes are still out of our reach. The results 
presented here should pave the way towards the higher resolution structure of a 
complete PIC and initially transcribing complexes in the future.  
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